Application of immunohistochemistry in the diagnosis and classification of acute leukemia by Priya, S
APPLICATION OF 
IMMUNOHISTOCHEMISTRY IN THE 
DIAGNOSIS AND CLASSIFICATION OF 
ACUTE LEUKEMIA 
by 
Dr S PRIYA 
 
A thesis submitted to 
 
THE TAMILNADU DR.M.G.R MEDICAL UNIVERSITY, 
CHENNAI 
 
 
in partial fulfillment of the requirements for the award of the degree of 
 
M.D in PATHOLOGY 
 
 
 
DEPARTMENT OF PATHOLOGY 
PSG INSTITUTE OF MEDICAL SCIENCE & RESEARCH 
PEELAMEDU, COIMBATORE- 641 004 
TAMILNADU, INDIA 
 CERTIFICATE 
 
This is to certify that the dissertation work entitled “Application 
of Immunohistochemistry in the Diagnosis and Classification 
of Acute Leukemia” submitted by Dr.S.Priya is a work done by 
her during the period of study in this department from 30/05/2010 
to 29/05/2013. This work was done under the guidance of 
Dr.T.M.SubbaRao, Professor, Department of Pathology, PSG 
IMS&R. 
 
 
 
 Dr. Alamelu Jayaraman                            Dr.S.Ramalingam 
Professor & HOD, Pathology                               Principal 
        PSGIMS & R                                            PSGIMS & R 
     Coimbatore – 04                                        Coimbatore – 04 
 
 
 
 
 CERTIFICATE 
 
This is to certify that the thesis entitled “Application of 
Immunohistochemistry in the Diagnosis and Classification of 
Acute Leukemia” submitted by Dr.S.Priya to The Tamilnadu Dr 
MGR Medical University, Chennai, for the award of the degree of 
Doctor of Medicine in Pathology, is a bonafide record of 
research work carried out by her under my supervision. The 
contents of this thesis, in full or in parts, have not been submitted 
to any other Institute or University for the award of any degree or 
diploma. 
 
 
 
 
Coimbatore  Dr T M SubbaRao 
10.12.2012   Professor of Pathology 
  PSG IMS&R 
  Coimbatore - 641004 
 
                                 
 
TABLE OF CONTENTS 
  
Page No. 
 
Certificate 
 
 
 
IHEC Clearance Certificate 
 
 
 
Acknowledgement 
 
 
1. Introduction 1 
2. Aims And Objectives 3 
3. Review Of Literature 4 
4. Materials And Methods 50 
5. Results 67 
6. Discussion 80 
7. Summary And Conclusions 93 
8. Bibliography 
 
9. Master Chart 
 
 
PSG Institute of Medical sclences & Research
Institutional Human Ethics Committee
POST BOX NO. 1674, PEELAMEDU, COIMBATORE 641004, TAMIL NADU, INDIA
Phone: 91 422 - 2598822, 2570170, Fax: 91422 - 2594400, Email: psgethics2005@yahoo.co.in
PROPOSAL NUMBER 10/265
PROJECT TITLE
Application of immunohistochemistry in the diagnosis and classification of
acute Leukemia
NAME OF THE INVESTIGATOR Dr S Priya
NAME OF THE GUIDE Dr T M Subba Rao
WAIVER OF CONSENT No
REVIEW TYPE Exempt
DATE OF THE MEETING N/A
DECISION Re-approved
APPROVAL DATE 21.12.2011
VALIDITY OF THE APPROVAL upto 02.01.2013
CONTINUING PANEL REVIEW Not Needed
" . \~\\.
')-\ \. "\
Dr Y S Sivan
Member - Secretary
Institutional Human Ethics Committee
ACKNOWLEDGEMENT 
 
I am extremely grateful and highly indebted to my guide Dr. Tadury 
Madhukar Subba Rao, Professor of Pathology for his guidance, support 
and constant enthusiasm at all stages of my study. But for his 
encouragement, this study would not have been possible. 
I am thankful to our Head of the Department, Dr. Alamelu Jayaraman, 
Professors Dr. V. Nirmala and Dr. S. Shanthakumari, Associate 
Professors and all Assistant Professors for their support and motivation. 
I am also obliged to all of my postgraduate colleagues and the staff 
members of Department of Pathology, for their help in data mining, retrieval 
of blocks, and technical support. I would like to thank in particular, Mrs. 
Angeline Mary, senior laboratory technician, for performing the 
immunohistochemical studies, the core of my thesis work. 
I am grateful to my daughters for their love, my parents for their prayers and 
blessings, my brother for motivating me and providing me with all the 
references whenever requested for, and to my husband for his constant 
inspiration, which gave me strength and self-confidence in completing the 
study. 
I am exceedingly thankful to all the patients of our hospital, whose data and 
tissue blocks helped me to perform the study. I pray for their good health. 
Last but never the least, I thank the almighty God for his kindness bestowed 
upon me. 
 
                                                                                                    Dr. S. Priya. 
 
LIST OF COMMONLY USED ABBREVIATIONS  
 
 
ABBREVIATION             EXPANSION 
WHO World Health Organization 
IARC International Agency For Research On Cancer 
AML Acute Myeloid Leukemia 
ALL Acute Lymphoblastic Leukemia 
MDS Myelodysplastic Syndrome 
MPD Myeloproliferative Disorder 
FAB French American British 
MPO Myeloperoxidase 
PAS Periodic Acid Schiff 
TdT Terminal Deoxynucleotidyl Transferase 
CD Cluster of Differentiation 
IHC Immunohistochemistry 
FC Flow Cytometry 
 
INTRODUCTION 
 
1 
 
Acute leukemias are characterized by neoplastic proliferation of 
hematopoietic stem cells and accumulation of blasts and immature cells in 
the bone marrow. They are broadly classified into two main groups viz., 
Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL), 
based on the cellular presentation of the primary stem cell defect. If 
maturation and differentiation of common myeloid progenitor cell is 
defective, the leukemia is classified as Acute Myeloid Leukemia and is 
characterized by clonal expansion of myeloid blasts. On the contrary if the 
maturation and differentiation of common lymphoid progenitor cell is 
defective, the leukemia is classified as Acute Lymphoid Leukemia and is 
characterized by clonal expansion of lymphoid blasts in peripheral blood, 
bone marrow or other tissues.  
The World Health Organization (WHO) further sub classifies these 
neoplasms based on morphology, cytochemistry, immunophenotyping, 
cytogenetic and molecular genetic studies. 
In our institute, the diagnosis and typing of acute leukemias rested 
principally on morphological assessment and enzyme cytochemical studies. 
In a few cases the typing of acute leukemia could be accurately established. 
However in quite a few cases, the typing of acute leukemia by these two 
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parameters alone was not possible. A general diagnosis of acute leukemia 
was offered in such situations. This caused a dilemma to in-house 
physicians as treatment protocols and prognostic outcomes for AML and 
ALL are significantly different. Till recently, the gold standard for diagnosis 
and typing of acute leukemias (that could not classified based on 
morphology & cytochemistry alone), rested on flow cytometry. This is 
available in very few select centres and is expensive. Review of recent 
literature reveals that immunohistochemistry itself can now be used to 
identify the lineage of leukemic blasts and is an acceptable gold standard. 
Currently, we are using immunohistochemistry for tissue sections and the 
department has standardized the protocols for their application on bone 
marrow trephine biopsy sections. There are many immunohistochemical 
markers that could be used, but it is important for centres to develop their 
own panels that would be cost-effective and specific. We therefore, would 
like to observe, if the application of a specific panel of 
immunohistochemical markers on the bone marrow trephine tissue sections 
of acute leukemia, would aid in their diagnosis and typing.       
AIMS & OBJECTIVES 
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1. To observe the utility of a selective panel of 
immunohistochemical markers to diagnose and classify acute 
leukemia. 
 
2. To compare the results of immunohistochemistry with the results 
of morphology and cytochemistry in acute leukemia. 
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ETYMOLOGY OF LEUKEMIA AND CLASSIFICATION 
SYSTEMS: 
In 1827, the first case of leukemia was described by a French 
physician, Alfred-Armand-Louis-Marie Velpeau in a 63-year-old 
florist with symptoms of fever, weakness, urinary calculi and 
significant hepatosplenomegaly. He observed that the patient’s blood 
had‘gruel’ like consistency and speculated that it could be because of 
the presence of white blood cells. [1]  
In 1845, J.H. Bennett, an Edinburgh pathologist described a term 
‘leucocythemia’ to denote a pathological condition in a series of 
cases, who died with splenomegaly and also had changes in their 
blood colour and consistency. In 1856, the German pathologist, 
Rudolf Virchow, coined the term ‘leukemia’. It was he who first 
described that abnormally excess white blood cells were present in 
blood of patients with symptoms described by Velpeau and Bennett. 
As he was not certain of the etiology, he used the descriptive term 
‘leukemia’ (Greek; white blood) to refer this condition. In 1878, the 
term myeloid was introduced by Franz Ernst Christian Neumann.  He 
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was the first person to identify that white blood cells are produced in 
the bone marrow (Greek; myelos- marrow). [2] 
In 1879, Mosler introduced the concept of bone marrow examination 
for diagnosing leukemia. [3] 
In 1891, the technique of staining blood films was described by Paul 
Ehrlich. He also described the morphology of normal and atypical 
white blood cells. [4]  
In 1889, Wilhelm Ebstein described the term ‘acute leukemia’ to 
differentiate rapidly progressive ones which cause immediate death, 
from, more slowly progressive and indolent chronic leukemias. [5]  
In 1900, Otto Naegeli, classified leukemias into two groups, namely, 
the myeloid and lymphocytic leukemia. He also described that the 
malignant cell in Acute Myeloid Leukemia (AML), was the 
myeloblast. [6] 
In 1913, leukemias were classified into four main types as chronic 
lymphocytic leukemia, chronic myelogenous leukemia, acute 
lymphocytic leukemia (ALL) and acute myelogenous leukemia 
(AML). [2] 
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In 1976, French American British (FAB) co-operative group 
classification was proposed which sub classified AML into 6 groups 
(M1 – M6) and ALL into 3 groups (L1 – L3). [7] 
In 1981, the FAB classification was revised and a simple scoring 
system for types L1 and L2 was proposed. [8]  
In 1985, another subtype named M7 was added to the FAB 
classification of AML. [9] In addition to the morphology, 
immunophenotyping was also used to diagnose this subtype. [10]  
In 1991, another subtype M0 was included in the FAB classification 
of AML.  Immunophenotyping, immunocytochemistry and electron 
microscopy were used to differentiate this subtype from ALL 
because, the morphology of AML M0 and ALL L2 blasts were very 
similar. [11] 
In 1999, the World Health Organization (WHO) and the International 
Society of Hematology proposed a new classification of acute 
leukemias which was published in the year 2001, in the WHO 
classification of tumors of hematopoietic and lymphoid tissue. 
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In 2004, a revision of the original 2001 WHO classification was 
proposed, and it was published in 2008. This classification is 
followed till date. 
In 2008, the genome of AML was fully sequenced. It is the first 
cancer whose genome is fully sequenced. [12]  
DEFINITION OF ACUTE LEUKEMIA – THEN & NOW: 
The FAB classification system had defined acute leukemias as 
neoplasms with presence of 30% or more of blasts in peripheral blood 
or bone marrow.  
The WHO classification of tumors of hematopoietic and lymphoid 
tissue published in 2001 defined acute myeloid leukemias as 
neoplasms with presence of > 20% myeloblasts in peripheral blood or 
bone marrow.  
There is no agreed upon consensus for acute lymphoblastic leukemias 
although, treatment centers treated only those with > 25% 
lymphoblasts in peripheral blood or bone marrow. These criteria have 
been retained in the most recent WHO classification of tumors of 
hematopoietic and lymphoid tissue published in 2008. [19] 
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OVERVIEW ON THE CLASSIFICATION SYSTEMS OF 
LEUKEMIA: 
i) FAB CLASSIFICATION: 
A team of seven French, American and British hematologists formed 
a FRENCH-AMERICAN-BRITISH CO-OPERATIVE GROUP and 
started working on cases of acute leukemia with the objective of 
achieving an uniform and consistent system of classification and 
nomenclature, utilizing the various cell surface antigens that were  
recently discovered and were thought be characteristic of particular 
cell types. 
The members individually examined Romanowsky stained peripheral 
blood smears and bone marrow aspirates of 150 patients of acute 
leukemia. A meeting was held in Paris in October 1974, and the 
participants discussed the diagnosis made by each one of them and if 
there was some difference in diagnosis, the slides were reexamined. 
They worked again on the slides for 8 more months and in July1975, 
they reached a general agreement and presented the classification 
after examining some more slides of acute leukemia. [7] 
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The classification was based on the morphology of predominant cell type in 
Romanowsky stained smears of peripheral blood and bone marrow which 
included the size of the cell, nuclear cytoplasmic ratio, presence of granules, 
and degree of basophilia in the cytoplasm. The morphology was 
supplemented using cytochemical reactions with myeloperoxidase, Sudan 
black B and non-specific esterase (naphtholAS- or ASD-acetate) before and 
after exposure to sodium fluoride. 
 In this classification, the diagnosis of acute leukemia required the presence 
of 30% blasts in the blood or bone marrow. [7]   
ACUTE LYMPHOBLASTIC LEUKEMIA: 
ALL was sub typed into 3 categories based on specific morphological 
features. They are detailed in table 1. 
ALL accounted for <1% of all cancers in adults while in children less than 
20 years of age, it comprised 25% of all cancers. 
Of the 3 types of ALL, ALL L1 was the most common type and accounted 
for more than 85% of childhood leukemias. 
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Table 1:  Morphological features of Acute Lymphoblastic Leukemias [7] 
Cytological 
features L1 L2 L3 
Cell size Small cells predominate 
Large, heterogeneous in 
size 
Large and 
homogeneous 
Nuclear 
chromatin 
Homogenous in 
any one case 
Variable-heterogeneous 
in any one case 
Finely stippled 
and 
homogeneous 
Nuclear 
shape 
Regular,occasional 
clefting or 
indendation 
Irregular; clefting and 
indentation common 
Regular, oval to 
round 
Nucleoli 
Not visible, or 
small and 
inconspicuous 
One or more present, 
often large 
Prominent; one or 
more 
vesicular 
Amount of 
cytoplasm Scanty 
Variable; often 
moderately abundant 
Moderately 
abundant 
Basophilia of 
cytoplasm 
Slight or 
moderate, rarely 
intense 
Variable; deep in some Very deep 
Cytoplasmic 
vacuolation Variable Variable Often prominent 
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ACUTE MYELOID LEUKEMIA: 
The FAB cooperative group suggested 6 subtypes of AML as shown in 
table2. 
Table 2:  Subtypes of Acute Myeloid Leukaemia – FAB classification. [7] 
SUBTYPE CHARACTERISTICS 
M1 Myeloblastic leukemia without maturation 
M2 Myeloblastic leukemia with maturation 
M3 Hypergranular promyelocytic leukemia 
M4 Myelomonocytic leukemia 
M5 
Monocytic leukemia 
a – Poorly differentiated (monoblastic)  
b – Differentiated   
M6 Erythroleukemia 
 
Myeloblastic leukemia without maturation (M1): 
AML without maturation constituted 5 – 10% of cases of AML. It 
commonly presented in adults and the average age at presentation was 46 
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years. Myeloblasts were abundant and comprised more than 90% of the non 
erythroid cells. [13] 
Bone marrow showed few cells (no more than 10%) with granulocytic 
differentiation. The blasts were homogenous, large, non granular, with 
occasional blasts showing Auer rods and /or cytoplasmic granules. They had 
one or more nucleoli. Myeloperoxidase positivity was seen in 3% or more of 
the blasts. 
Myeblastic leukemia with maturation (M2): 
This accounted for about 10% of total cases of AML and presented in all 
age groups. The clinical presentations of the patients were with symptoms 
related to pancytopenia. [13]  
More than 10% cells of the bone marrow showed evidence of granulocytic 
differentiation and maturation including promyelocytes, myelocytes, 
metamyelocytes and granulocytes. Blasts accounted for 20 – 89% of non 
erythroid cells.   The blasts had varying amounts of cytoplasm, most of them 
with granules and had one or more nucleoli. Many blasts contained single 
Auer rods.  The cells could show dysplasia including lobulations in nuclei of 
myeloblasts, hypogranular myeloblasts and granulocytes could show hypo 
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or hyper lobated nuclei. Blasts were positive for myeloperoxidase and 
Sudan black B. 
Hypergranular Promyelocytic Leukemia (M3): 
5 – 8 % of AML was acute promyelocytic leukemia. This occurred most 
commonly in adults. Patients could present with features of disseminated 
intravascular coagulation. [14]  
Bone marrow cells were predominantly abnormal promyelocytes with 
abundant granules in the cytoplasm (hyper granular promyelocytes). The 
nucleus showed anisopoikilosis and was often bilobed, indented or reniform 
shaped with one or more nucleoli. The cytoplasm was completely studded 
with coalescent large granules that obscured the nuclei. The granules were 
red, deep pink or purple in Romanowsky stained smears. Fine dust like 
granules could also be found in some cells. The characteristic cells in AML 
M3 were those with abundant Auer rods that could be present as criss-cross 
bundles (‘Faggot’) frequently seen in bone marrow and even in peripheral 
blood in a few cases. 
 
Myelomonocytic Leukemia (M4): 
Acute myelomonocytic leukemia accounted for about 5 – 10% of cases of 
AML. It more often presented in older age group with an average age at 
REVIEW OF LITERATURE 
 
14 
 
presentation of 50 years. The patients most often presented with tiredness, 
fever, anemia, leukocytosis and with low platelet counts. [13] 
This type showed proliferation of both monocytic and granulocytic 
precursors in the bone marrow. The diagnosis required the presence of 
following features viz., blasts greater than 20%, monocytic component 
greater than or equal to 20% and granulocytic component greater than or 
equal to 20% of non-erythroid nucleated cells in the bone marrow and/or 
peripheral blood monocytic component (monoblasts, promonocytes and 
monocytes) greater than 5 x 109/L. Myeloblasts had varying amounts of 
cytoplasm, most of them with granules. They had one or more nucleoli and 
many blasts contained single Auer rods. Monoblasts were usually large with 
abundant cytoplasm that is bluish gray in colour and showed fine granules, 
pseudopods or vacuolations. The nucleus was round or convoluted with 
delicate lacy chromatin and one or more nucleoli. Myeloblasts were 
myeloperoxidase and Sudan black B positive and monoblasts were naphthol 
AS-D chloroesterase and alpha- naphthyl acetate esterase positive.  
 
Monocytic Leukemia (M5): 
This accounted for less than 5% of all cases of AML. The median age at 
presentation was 49 years with a slight male predominance. These patients 
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often had central nervous system, skin and gingival involvement. Extra 
medullary masses and bleeding tendencies were known to occur frequently 
in these cases. [13] This type AML was characterized by the presence of 
greater than or equal to 80% cells of monocytic lineage (monoblasts, 
promonocytes and monocytes). The granulocytic component was less than 
20% of the nucleated cells in the marrow. 
There are two subtypes a) poorly differentiated (monoblastic). 
                                       b) differentiated.  
a) Poorly differentiated subtype was characterized by the presence of 
abundant large monoblasts in the peripheral blood and bone marrow. The 
blasts had abundant cytoplasm some with pseudopods (lighter in colour than 
the rest of cytoplasm) and occasional granules. The nucleus was round or 
convoluted with delicate lacy chromatin and had prominent and large 
nucleoli which were also vesicular and varied in number from one to three 
or more. Only few promonocytes were seen. 
b) Differentiated subtype showed all the cells of monocytic series including 
monoblasts, promonocytes and monocytes. The promonocyte was the 
predominant cell in the bone marrow and peripheral blood showed a large 
number of monocytes. The promonocyte had a grayish cytoplasm with a 
ground glass appearance and fine granules. The nuclei were irregular, large 
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and convoluted (cerebriform appearance). The diagnosis was confirmed by 
the cytochemical reactions. These cells were positive for nonspecific 
esterase and inhibited with fluoride. 
Erythroleukemia (M6): 
This accounted for < 5% of all cases of AML and occurred primarily in 
adults. In this type, the erythroblasts and myeloblasts accounted for more 
than 50% and 20% of bone marrow nucleated cells, respectively. The 
erythroblasts demonstrated abnormal and bizarre morphology which 
included nuclear budding, nuclear fragmentation, megaloblastic changes, 
cytoplasmic vacuoles, karyorrhectic debris, giant multinuclear forms and 
ringed sideroblasts. The nuclei could be bilobed or multilobated. 
Erythroblasts could be seen in peripheral blood. Granulocytic cells showed 
myeloblasts with Auer rods and promyelocytes. Dysmegakaryopoiesis was 
seen in the form of micromegakaryoblasts and mononuclear 
megakaryocytes. 
Revised FAB classification:  First revision - 1981: [8] 
The first revision was the result of a review of 300 slides of ALL (done 
twice) to assess for the concordance in the ALL classification that was 
based on cell morphology. Based on a series of discussions, the FAB 
proposed a simpler scoring system for ALL type L1 and ALL type L2. Four 
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morphological features were the strength of character for this review. They 
were: 
i. Nuclear – cytoplasmic ratio 
ii. Nucleolar features such as absence, presence, number and 
prominence 
iii. Nuclear membrane outline (regular or not) and  
iv. The size of the cell.  
Using this method, there was an increase in the overall concordance (84% 
from 63%) between the seven observers. There was a drastic difference in 
the morphological types of ALL between children (≤ 15 years) and adults (≥ 
15 years). The most common type of ALL in children was L1 which 
accounted for 74% of cases, but the most common ALL in adults (66% of 
cases) was L2. The prognosis of L1 was better than L2 and the latter had a 
higher relapse rate. 
Revised FAB classification:  Second revision – 1985: [9] 
In 1985, another category called M7 was added by the FAB cooperative 
study group. The M7 referred to acute leukemia involving the 
megakaryocyte lineage. The advances in immunophenotyping resulted in 
the reporting of this type and its subsequent inclusion in the classification 
system of AML. 
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A panel of members of South-West oncology group reviewed the slides of 
acute leukemia to check for the reproducibility of FAB classification of 
acute leukemia into AML and ALL by morphology and cytochemistry. The 
various limitations of this classification were analyzed. They proposed that 
some of the cases of M1, M2 and M4 could be merged into this new 
category, M7.  [9], [15] 
Megakaryoblastic leukemia (M7): 
This subtype added by the FAB revision in 1985 was rare and accounted for 
less than 5% cases of AML and could present in both children and adults. In 
young male patients, a link between acute megakaryoblastic leukemia and 
occurrence of germ cell tumors in mediastinum was noted. [13] 
AML M7 was characterized by the presence of 50% or more blasts of 
megakaryocytic lineage. These blasts had considerable variation in their size 
and ranged from to small round cells with basophilic agranular cytoplasm 
and dense condensed chromatin to large cells with abundant cytoplasm with 
blebs, with or without granules. The nucleus had single or multiple 
prominent nucleoli. The blasts could be confirmed as megakaryocytic 
lineage by immnunophenotyping (CD 41 or CD 61) or by ultrastructural 
demonstration of platelet peroxidase by electron microscope. The peripheral 
blood of these patients usually showed pancytopenia or rarely leukocytosis.  
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Revised FAB classification:  Third revision - 1991: [11] 
In 1991, the FAB cooperative study group added another new category of 
AML to their classification called AML- M0 (AML with minimal 
differentiation). They further stated that AML M0 blasts were very identical 
to lymphoblasts (most commonly L1 or rarely L2 type) in being large and 
agranular. Hence, AML M0 myeloblasts and ALL L1/L2 lymphoblasts 
could not be distinguished by morphology alone. They suggested certain 
criteria for the diagnosis of AML M0 which are stated below. [11] 
• The blasts show negative cytochemical staining for myeloperoxidase 
• Staining for Sudan black B should either be negative or if positive, 
the positivity should be present in less than 3% blasts. 
• Immunophenotyping should reveal at least one positive myeloid 
marker CD 13 or CD33. 
• The presence of myeloperoxidase enzyme should be confirmed either 
by electron microscopy or by immunocytochemistry. 
• Immunophenotyping should also confirm the absence of B and T 
lineage of the blasts. 
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AML M0: 
This subtype represented <5% of all cases of AML and presented at both the 
extremes of age. The clinical presentation is usually with symptoms related 
to pancytopenia. [13] 
The blasts were of medium size with agranular cytoplasm and the nuclei 
were either round or had indentations. Nucleoli were present and were 
variable in number. In most cases, the bone marrow was hypercellular with 
sheets of undifferentiated blasts. These blasts could not be differentiated 
from lymphoblasts by morphology or cytochemistry and hence 
immunophenotyping or ultrastructural studies were mandatory to diagnose 
this subtype.  
 
ii) WHO CLASSIFICATION - 2001: 
World over, acute leukemias were classified based on the FAB system while 
lymphoid neoplasms were classified based on the Revised European-
American Classification of Lymphoid Neoplasms (REAL). There was no 
standardized classification for other hematopoietic neoplasms such as 
chronic leukemias, myeloproliferative neoplasms, histiocytic neoplasms etc. 
The WHO along with the International Society of Hematopathology and 
European Association of Hematopathology proposed a new classification 
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addressing these issues. This was a collaborative effort of over 100 
pathologists, scientists and clinicians throughout the world. Their clinical 
and research publications contributed a lot to arrive at this classification. A 
meeting was held at Airlie, Virginia in USA and cytogenetic abnormalities 
were added to the classification. [16] 
 The WHO classification of tumors of hematopoietic and lymphoid tissue 
which was published in 2001 echoed a paradigm shift in the approach to the 
classification of hematopoietic neoplasms. Apart from morphology, this 
classification also incorporated clinical, genetic and immunophenotypic 
features. The broad headings under which these tumors of the hematopoietic 
and lymphoid tissues were classified was: [17] 
i)  Chronic Myeloproliferative Diseases 
 
ii)  Myelodysplastic / Myeloproliferative Diseases 
 
iii)  Myelodysplastic Syndromes 
 
iv)  Acute Myeloid Leukemias 
 
v)  B cell neoplasms 
 
vi)  T cell and NK cell neoplasms 
 
vii) Hodgkin Lymphoma 
 
viii) Histiocytic and dendritic-cell neoplasms and 
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ix)  Mastocytosis 
 
 
The salient features of this classification with respect to acute myeloid 
leukemia are as follows: [17] 
 
• The cut off for blast cells in the peripheral blood or bone marrow for the 
diagnosis of acute myeloid leukemia was brought down to 20% from the 
previous 30% requirement in FAB classification. 
• Monoblasts and promonocytes in acute monoblastic                      
/ monocytic leukemia, megakaryoblasts in acute megakaryoblastic 
leukemia and promyelocytes in acute promyelocytic leukemia were 
regarded as ‘blast equivalents’, while calculating the blast percentage for 
the diagnosis of AML. 
• Erythroblasts were excluded from the blast count except in cases of 
‘pure’ erythroleukemia. 
• Another cell excluded from blast count was the dysplastic 
micromegakaryocyte.     
• AML was categorized into 5 subheadings as shown in table 3. 
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TABLE 3: WHO 2001 classification of AML [17] 
I. AML WITH RECURRENT GENETIC ABNORMALITIES 
i. AML with t(8;21)(q22;q22).AML1/ ETO  
ii. AML with abnormal bone marrow eosinophils and (inv 
16(p13q22) or t (16; 16) (p13;q22). CBFβ / MYH11  
iii. Acute promyelocytic leukemia with t(15;17)(q22;q12). 
PML/RARα and variants 
iv. AML with 11q23(MLL) abnormalities 
II. AML WITH MULTILINEAGE DYSPLASIA 
i. Following MDS or MDS/MPD 
ii. Without antecedent MDS or MDS/MPD, but with dysplasia in at 
least 50% of cells in 2 or more myeloid lineages 
III. AML  AND MDS- THERAPY RELATED 
i. Alkylating agent / radiation – related type 
ii. Topoisomerase II inhibiter – related type 
iii. Others 
IV. AML, NOT OTHERWISE CATEGORIZED 
i. Acute myeloid leukemia, minimally differentiated 
ii. Acute myeloid leukemia without maturation 
iii. Acute myeloid leukemia with maturation 
iv. Acute myelomonocytic leukemia 
v. Acute monoblastic/ acute monocytic leukemia 
vi. Acute erythroid leukemia (erythroid/myeloid and pure 
erythroleukemia) 
vii. Acute megakaryoblastic leukemia 
viii. Acute basophilic leukemia 
ix. Acute panmyelosis with myelofibrosis 
x. Myeloid sarcoma 
V. ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE 
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The salient features of this classification with respect to acute lymphoblastic 
leukemia are as follows: [17] 
• They are grouped under one major heading ‘Precursor B-cell & T-cell 
neoplasms’. 
• The Precursor B-cell neoplasm, also known as Precursor B ALL and 
the Precursor T-cell neoplasm, also known as Precursor T ALL, were 
together equivalent to the morphological types L1 & L2 of FAB 
system. 
• Patients with a mass lesion and <25% blasts in the bone marrow were 
designated as lymphoblastic lymphoma, while if it was >25%, it 
could be diagnosed as lymphoblastic leukemia. 
• The categorization of ALL as pre-B or pre-T was to be made using 
immunophenotyping. While both of these blasts were positive for 
TdT, the former were also positive for CD19 and CD20 while the 
latter were positive for CD 3 and CD7. 
 
iii) WHO CLASSIFICATION - 2008: 
 The spectacular advancement in the field of molecular genetics in the past 
decade, the discovery of various new molecular abnormalities in AML and 
ALL and increase in targeted gene therapy regimens resulted in revised  
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classification by the WHO in 2008.  This classification is the most recent 
and in vogue. 
Some of the salient changes made are listed below: [18] 
• Chronic myeloproliferative diseases were renamed as myeloproliferative 
neoplasms which included mastocytosis as one of its types. 
• A new category of diseases characterized by specific cytogenetic 
abnormalities and eosinophilia was introduced. 
• Two more entities were added onto the list of AML with recurrent 
genetic abnormalities. 
• Acute leukemias of ambiguous lineage was removed from AML 
category and made an independent entity.  
• Precursor lymphoid neoplasms included 3 subcategories. The pre – B 
was split as those with recurrent genetic abnormalities and those without, 
the latter called as not otherwise specified (NOS). 
• ALL- Burkitt leukemia (L3 of FAB) was placed under mature B-cell 
neoplasms. 
Table 4 lists neoplasms categorized under precursor lymphoid neoplasms 
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TABLE 4: WHO 2008 CLASSIFICATION OF PRECURSOR LYMPHOID 
NEOPLASMS 
B LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA 
A] B lymphoblastic leukemia/ lymphoma, NOS 
B] B lymphoblastic leukemia/ lymphoma with recurrent genetic 
abnormalities 
i. B lymphoblastic leukemia/ lymphoma with t(9;22)(q34;q11.2); BCR- 
ABL1 
ii. B lymphoblastic leukemia/ lymphoma with t(v;11q23); MLL 
rearranged 
iii. B lymphoblastic leukemia/ lymphoma with t(12;21)(p13;q22); TEL- 
AML1 (ETV6 – RUNX1) 
iv. B lymphoblastic leukemia/ lymphoma with hyperdiploidy 
v. B lymphoblastic leukemia/ lymphoma with hypodiploidy 
vi. B lymphoblastic leukemia/ lymphoma with t(5;14)(q31;q32); IL3 – 
IGH 
vii. B lymphoblastic leukemia/ lymphoma with t(1;19)(q23;p13.3); E2A – 
PBX1 (TCF3 -  PBX1) 
T LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA 
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B LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA - NOS: 
This represents 80 – 85% of all cases of ALL in children and 70% of cases 
in adults. The lower limit of lymphoblasts required to make a diagnosis of 
ALL is not specified, contrary to AML. A diagnosis of ALL was to be 
avoided if lymphoblasts were <20%. However, the WHO states that a 
lymphoblast percentage of 25% and above in the bone marrow is used as a 
cut off for definition of leukemia, in many treatment protocols. [19]. There is 
no clarity on cases where the lymphoblast percentage was in between these 
two figures. Patients usually present with symptoms related to bone marrow 
failure and enlargement of liver and spleen. Lymphoblasts are heterogenous 
and range from small cells having condensed chromatin and inconspicuous 
nucleoli to large blasts with grey blue cytoplasm (sometimes vacuolated, 
10% may show granules, some show pseudopods imparting a‘hand mirror’ 
appearance), dispersed chromatin and many nucleoli. The nuclei may be 
round or oval, frequently irregular and may show convolutions.  
B LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA WITH 
RECURRENT CYTOGENETIC ABNORMALITIES: 
The lymphoblasts listed in this category do not have any morphologic or 
cytochemical features that are different from those without recurrent genetic 
REVIEW OF LITERATURE 
 
28 
 
abnormalities. The WHO justifies the need to perform cytogenetic studies in 
ALL because those that are positive have distinctive clinical properties and 
prognostic implications.  
For instance, those with t (9; 22) (q34; q11.2) have a poor prognosis unless 
treated with Imatinib. ALL with t (v; 11q23) is the most common leukemia 
in infants < 1 year of age and has a high frequency of CNS involvement at 
diagnosis rendering a poor prognosis. More than 90% of ALL children with 
t (12; 21) or hyperploidy have had complete cures. 
T lymphoblastic leukemia/ lymphoma: 
This represents 15% of all cases of childhood ALL and 25% of cases in 
adult population. It occurs more frequently in adolescent males. They 
usually present as huge mediastinal masses along with hepatosplenomegaly 
and lymph node enlargement. The lymphoblasts vary in size from medium 
sized cells with highly condensed chromatin and absent nucleoli to larger 
blasts which show dispersed chromatin and prominent nucleoli. The nuclei 
may be round or frequently irregular and some may show convolutions.  
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DETAILS OF THE WHO 2008 CLASSIFICATION OF ACUTE 
MYELOID LEUKEMIA: 
AML is classified into 6 main groups as shown in table 5. The key changes 
vis-à-vis the 2001 classification are discussed. 
1. AML with recurrent genetic abnormalities  
*AML with t(8;21)(q22;q22), AML with inv(16)(p13.1;q22) or 
t(16;16)(p13.2;q22) and acute promyelocytic leukemia with 
t(15;17)(q22;12) are considered AML regardless of blast count. Other 
genetic abnormalities should have a minimum of 20% blasts to be diagnosed 
as acute leukemia. 
*Only cases with t (15;17)(q22;q12) PML – RARA were regarded as Acute 
promyelocytic leukemia. Cases with variant RARA translocations such as 
ZBTB16 – RARA, NUMA – RARA, NPM1 – RARA and STAT5B – 
RARA were recognized separately as they show different morphology such 
as absent Auer rods, nuclei which are regular and numerous neutrophils 
with Pelgeroid morphology and strong cytochemical reaction for 
Myeloperoxidase. Cases with ZBTB16 and STAT5B – RARA fusions 
showed resistance to treatment with All trans retinoic acid. 
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Table 5: WHO 2008 classification of AML 
1.AML WITH RECURRENT GENETIC ABNORMALITIES 
i. AML with t(8;21)(q22;q22); RUNX1- RUNX1T1 
ii. AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB- MYH11 
iii. Acute promyelocytic leukemia with t(15;17)(q22;q12); PML – 
RARA 
iv. AML with t(9;11)(p22;q23); MLLT3 – MLL 
v. AML with t(6;9)(p23;q34); DEP – NUP214 
vi. AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1 – EVI1 
vii. AML(megakaryoblastic) with t(1;22)(p13;q13); RBM15 – MKL 1 
viii. AML with mutated NPM1 
ix. AML with mutated CEBPA 
2. AML WITH MYELODYSPLASIA RELATED CHANGES 
3. THERAPY RELATED MYELOID NEOPLASMS 
4. ACUTE MYELOID LEUKEMIA, NOS  
i. AML with minimal differentiation 
ii. AML without maturation 
iii. AML with maturation 
iv. Acute myelomonocytic Leukemia  
v. Acute monoblastic and monocytic Leukemia 
vi. Acute erythroid leukemia 
vii. Acute megakaryoblastic leukemia 
viii. Acute basophilic leukemia 
ix. Acute panmyelosis and myelofibrosis 
5. MYELOID SARCOMA 
6. MYELOID NEOPLASMS RELATED TO DOWN  SYNDROME 
i. Transient abnormal myelopoiesis 
ii. Myeloid leukemia associated with Down syndrome 
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* AML with MLL abnormalities was redefined as AML with t (9; 11) (p22; 
q23); MLLT3 – MLL. Any Abnormalities of MLL other than this 
translocation should not be included in this category of AML.   
* Three new genetic abnormalities were added to the list which includes 
t(6;9)(p23;q34); DEP – NUP214, inv(3)(q21q26.2) or t(3;3)(q21;q26.2); 
RPN1 – EVI1 and t(1;22)(p13;q13); RBM15 – MKL 1 to the previous 2001 
classification. 
* Two new mutations, AML with mutated NPM1 and CEBPA were added 
as   provisional entities. 
* It was strongly recommended that cases of AML which do not show any 
other cytogenetic abnormalities can be tested for Flt3 mutations.  
2. AML with myelodysplasia related changes. 
* The category AML with multi-lineage dysplasia in previous 2001 
classification was renamed as AML with myelodysplasia related changes. 
* Certain diagnostic criteria were used to assign AML cases to this category 
which includes the following: 
   - Past history of myelodysplastic syndrome which has evolved in to AML. 
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  - Presence of a cytogenetic abnormality related to myelodysplasia. 
   - If ≥ 2 myeloid cell lineages have ≥ 50% cells with dysplasia 
3. Therapy related myeloid neoplasms. 
In this group, the sub classifications have been removed. 
4. AML, NOS. 
* Cases of acute erythroid leukemia which harbor dysplasia are removed 
from the NOS category and reclassified as AML with myelodysplasia 
related changes. 
* In cases of acute megakaryoblastic leukemia, if any genetic abnormality 
such as inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1 – EVI1 or 
t(1;22)(p13;q13); RBM15 – MKL 1 was found, then it should be classified 
under the suitable category rather under AML, NOS. 
* This category should not include cases related to Down syndrome. 
5. A new category called myeloid proliferations related to Down syndrome 
is added. 
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LABORATORY FINDINGS IN ACUTE LEUKEMIAS: 
PERIPHERAL BLOOD SMEAR STUDY: 
Examination of a peripheral blood smear stained with May – Grunwald – 
Giemsa or Wright – Giemsa should be done to evaluate the abnormalities in 
the red blood cells, white blood cells and platelets. A manual differential 
count of 200 white blood cells must be done in all cases of AML. [20] 
Most of the patients with AML have anemia and thrombocytopenia. Red 
blood cells can be slightly macrocytic either because they are unable to 
compete with neoplastic cells for B12 and folic acid or their premature 
release as reticulocytes. Platelets may be hypogranular and rarely giant 
platelets can be observed. [21]    
The total leucocyte count and the percentage of blasts in AML are quite 
variable. [22] Neutrophils at times can show signs of dysplasia like 
hypogranulation, pseudo – pelger – huet anamoly etc. These features of 
myelodysplasia can be seen in any type of AML but is particularly common 
in acute promyelocytic leukemia. [23] But the percentage of blasts should be 
greater than 20% for the diagnosis of acute leukemia. Three different types 
of neoplastic blasts were defined by the FAB group which includes type I 
blasts with no granules, type II blasts with less than twenty granules, type III 
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blasts with abundant granules.[21] Generally a myeloblast has a size of 
approximately 20µm diameter, round to oval nuclei with dispersed 
chromatin and prominent nucleoli. Auer rods or granules can be seen in the 
cytoplasm of some of the blasts. 
60 – 70% of patients with ALL at presentation show an increase in the total 
white blood cell count ranging from 50 to 100 x 109/L. Approximately 25% 
of patients present with a decreased total leucocyte count. [24] There is 
marked neutropenia in these patients predisposing them to the risk of 
acquiring various infections. Thrombocytopenia is also present with an 
average range of 48- 52 x 109/L. In children the lymphoblasts are uniform, 
small and are about two times the size of a small lymphocyte. They have 
scant to moderate amounts of basophilic cytoplasm and the nucleus is 
usually round and may show indentations. Nucleoli are generally absent. 
But in adults, the blast population is heterogeneous with a mixture of 
smaller and larger lymphoblasts that posses moderate amounts of cytoplasm 
which is basophilic and may show few granules. Nuclei are irregular with 
prominent nucleoli.  [25]  
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BONE MARROW ASPIRATE (BMA) SMEAR STUDY: 
May – Grunwald – Giemsa or Wright – Giemsa stained, BMA smears 
should be examined and a perfect area for performing a 500 nucleated cell 
count should be chosen, which is close to the particle and should not be 
diluted with blood. If BMA yields a dry tap, then touch imprint can be made 
from the trephine biopsy core and morphology can be evaluated. However 
as the differential count on touch imprints will not be representative, it need 
not be done. [20]   
Usually the BMA smears of AML are hypercellular for age.  BMA with 
cellularity of ≤ 30% are referred to as hypoplastic or hypocellular AML. [22] 
As defined by the WHO, the blasts should be ≥ 20% of the nucleated non 
erythroid cells in the bone marrow for the diagnosis of AML to be made. 
Myeloblasts, monoblasts and megakaryoblasts should be included as blasts 
for the calculation of the blast count. Promonocytes and abnormal 
promyelocytes are ‘blast equivalents’ and should be included in the blast 
count while calculating the percentage of blasts.  Erythroblasts should 
usually be excluded from the blast count. Only in cases of ‘pure’ 
erythroleukemia, erythroblasts are considered as ‘blast equivalents’ and can 
be included in the total blast percentage [20]. In 50% of cases, Auer rods can 
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be seen within the blasts and in few cases the marrow may show an increase 
in fibrosis. [21] 
BMA smears in ALL are hyper cellular for age. Most cases show greater 
than 65% blasts at presentation. [25] Some lymphoblasts may show 
intracytoplasmic inclusions which may be of lysosomal origin. [26] 
Bone marrow trephine biopsy: 
An adequate biopsy should be taken at right angle to the cortical surface. 
The length of the biopsy should at least be 1.5 cm, as this would contain at 
least 10 partially preserved inter - trabecular areas for evaluation. The core 
should be adequately fixed. 3-4µm sections need to be cut and stained with 
haemotoxylin and eosin. A complete morphological assessment should be 
made and the following features are to be noted. 
1. Overall cellularity of the marrow 
2. Arrangement of cells (architecture) 
3. Proportion of various haematopoietic cells and their maturation. 
4. Stromal changes and fibrosis of the bone marrow. 
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Cytochemistry: 
Cytochemistry is used to identify the chemical composition of blasts by 
using color reactions and these stains are useful in the identification of blast 
lineage. They are commonly done on peripheral blood and BMA smears. 
When correctly performed they can be applied on tissue sections as well. [20] 
Myeloperoxidase (MPO) :  
Peroxidase enzymes are seen in the granules of myeloid cells. When stained 
with benzidine chromogens, a positive reaction is indicated by brown 
coloration of the granules.  
All myeloblasts stain positive for MPO except in those of minimally 
differentiated AML, where the number of positive blasts may be too low to 
be identified. Monoblasts are generally negative for MPO. However 
occasional monoblasts and a few promonocytes may show scattered fine 
positive granules. Megakaryoblasts, lymphoblasts and erythroblasts also 
show a negative reaction.  
Sudan Black B (SBB):   
SBB is a lipophilic dye and detects lipids in the granulocytes. The staining 
reaction is directly proportional to the stage of granulocyte maturation. 
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When stained using the Sheehan and Storey technique, a positive reaction is 
black and granular.  Myeloblasts stain positive. However the test is less 
specific than MPO. Rare lymphoblasts are also positive for SBB but the 
granules stain light grey in color when compared to the myeloblasts which 
stain deep black in color. [24]   
Esterase : 
Esterases are esters of carboxylic acids and can hydrolyze the ester bonds in 
aliphatic and aromatic aminoacids. Esterases with low specificity towards 
binding the substrate are called non-specific esterases whereas those with 
high specificity are referred to as specific esterases. These reactions are 
helpful in distinguishing the cells of neutrophil and monocyte series. [24] 
Non specific esterase (NSE):  
Two NSE used commonly are α naphthyl butyrate (ANB) and α naphthyl 
acetate (ANA). The ANB and ANA show diffuse cytoplasmic positivity in 
monoblasts and also in monocytes. Neutrophils do not stain for NSE and are 
negative. Erythryoblasts and megakaryoblasts can also show multifocal 
punctate positive staining reaction for nonspecific esterase but it will be 
partially resistant to inhibition by sodium fluoride (NaF). But the positive 
reaction of monocyte and monoblast to NSE can be totally inhibited by 
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sodium fluoride. Lymphoblasts exhibit focal punctate positivity (golgi zone 
pattern) to NSE and inhibition by NaF is variable. 
Specific esterase: 
Cells of neutrophil lineage exhibit positivity for Naphthol – ASD – 
choloroacetate esterase (CAE). Mast cells are also positive. Neoplastic 
eosinophils will be positive but normal eosinophils may be negative. 
Occasional cells in myelomonocytic leukemia will simultaneously stain 
positive for both specific and non-specific esterases.   
Periodic acid Schiff (PAS) : 
Carbohydrates with 1, 2 – glycol and glycogen show positivity for PAS 
stain. In this reaction, the periodic acid is oxidized to dialdehyde in the first 
step which is then demonstrated by adding Schiff’s reagent in the second 
step. Mature neutrophils (but not myeloblasts), platelets (both mature and 
immature forms) show strong positivity. Neoplastic proerythroblasts show 
large globules of PAS positivity and hence can be useful in the diagnosis of 
acute erythroid leukemia. Lymphoblast exhibits coarse granular or block – 
like positivity. 
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Immunophenotyping: 
Immunophenotyping is important tool in differentiating AML from ALL. It 
is also very useful in the immunologic sub classification of ALL into T, B or 
NK cell type which has important prognostic implications, as the T-cell 
ALL has a worse prognosis and is resistant to chemotherapy. It is of great 
advantage in identifying acute leukemias of ambiguous lineage (mixed 
phenotypic) and in the identification of minimal residual disease.  
Immunophenotyping can be done by performing immunohistochemistry on 
bone marrow trephine biopsy sections or by means of multiparameter flow 
cytometry.  This is based on the fact that different antigens which are 
expressed on the cells during each stage of normal hematopoiesis are also 
seen in the neoplasms that develop from the corresponding cells. Both 
surface antigens markers, monoclonal and polyclonal antibodies are used in 
the diagnosis. Table 6 shows the various surface antigens expressed on the 
myeloid lineage cells.  
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TABLE 6: Antigens expressed by myeloid cells 
Name of cell type Antigen(s) expressed 
Hematopoietic stem cell  CD 34 
Common myeloid progenitor cell CD 34, HLA – DR, CD 38  
Myeloblast  CD 34, HLA – DR, CD117, CD13, CD33 dim,  
Monoblast  CD 34, CD 4, CD 13, CD 33, HLA – DR 
Promonocyte CD 4, CD 13, CD 15, CD33, CD 36, HLA 
– DR, CD 11b, CD14 
Proerythroblast  CD117, CD 36 high, CD 235a low. 
Promyelocyte  CD 117, CD 13, CD 33, MPO, CD 65 
Megakaryoblast  CD34±, CD 38±, CD 61, CD41 
The various antigens expressed on the cell surface of lymphoid cell lineage 
is shown in table 7.  
Table 7: Antigens expressed by lymphoid cells 
Name of cell type Antigen(s) expressed 
Lymphoid Progenitor cell TdT 
Pro – B ALL TdT, cCD 22, CD 34, CD 19 
Intermediate pre – B CALL   TdT, CD19, CD 10, CD20±, c CD22 
Pre – B ALL CD19, CD 20, sCD 22, cIg (µ)  
 
Flow cytometry:  
Flow cytometry is used to detect antigens on the surface or inside the cell. 
The cell suspension is passed through a flow chamber and the light scattered 
by individual cells is detected by a photo detector. In addition, specific 
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antibodies labeled with fluorescent dyes are used. These antibodies bind the 
antigen of interest and emit fluorescent light upon excitation. This is 
detected by means of a photomultiplier tube and finally quantified.  
Multiparameter flow cytochemistry is the preferred method for 
immunophenotyping because of the following advantages. [27] 
• In a short time interval, a large number of cells can be analyzed. 
• Several antigens can be simultaneously studied on a single neoplastic 
cell. 
Flow cytometry is very useful in differentiating between minimally 
differentiated AML and ALL and is also used in the subtyping of AML and 
ALL. The disadvantages are that only fresh and viable cells or tissue can be 
used and the results cannot be correlated with morphology of cells. [28] 
Immunohistochemistry (IHC) on bone marrow trephine biopsy: 
Immunophenotyping can also be done by applying immunohistochemical 
markers to formalin fixed, routinely processed and paraffin embedded bone 
marrow trephine biopsy tissue. Recently immunohistochemistry is being 
increasingly used in bone marrow trephine biopsies. [29], [30]  
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In olden days, the use of IHC was restricted due to the unavailability of 
good affinity antibodies. At present improvement in techniques to retrieve 
the antigens and availability of various commercial antibodies have greatly 
influenced its wide spread use [31] 
Principles of IHC: [32] 
The tissue antigens are demonstrated by means of antigen antibody 
interactions. The binding site of antibody can be identified by two methods. 
• Direct technique -  The primary antibody itself is conjugated to either a 
flurochrome or an enzyme and this antibody directly binds with the 
antigen in tissues. 
• Two step indirect technique - The primary antibody which is unlabelled 
binds the antigen in tissues, which in turn is bound by a secondary 
antibody (labeled with an enzyme and a suitable chromogen substrate). 
Advantages: 
• It can be performed even on fixed and old archived tissue 
• It is particularly important in cases of bone marrow fibrosis, fatty 
marrow or extremely hypercellular marrow, in which aspirate is very 
scant or absent (dry tap). 
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• It is helpful in analyzing extremely fragile cells that cannot withstand 
the hydrodynamic focusing in flow cytometers. [33] 
• Antigens present in the cytoplasm and nucleus of the leukemic cells 
like myeloperoxidase and terminal deoxynucleotidyl transferase can 
be readily identified. But these antigens can be detected in 
flowcytometer only after membrane permeabilization, a difficult step 
to perform technically. 
• Architecture, cellularity and morphology can be assessed. 
Disadvantages: 
• Longer time required for processing  
• Subjective variation in interpretation of results 
• Only semiquantitative assessement of tumour cells is possible. 
• Only one antibody staining can be done per slide. 
• Only select antibodies are available for performing IHC.  
 Immunohistochemistry can be helpful in distinguishing AML from ALL. 
Orazi A, in his review article in the Pathobiology journal, listed the various 
markers used for this purpose. This is furnished in table 8.  
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Table 8: IHC markers used in distinguishing AML from ALL[23] 
AML 
CD34, CD103, MPO, HEMOGLOBIN, CD61, CD42b, CD68R, 
CD163, LYSOZYME, CD56. 
ALL 
CD34, TdT, CD10, CD79a, PAX5, CD20, CD3, CD7, CD2, 
CD5, CD7, CD4, CD8, CD1a. 
 
A wide panel of antibodies is required for immunophenotyping of the 
subtypes of AML and ALL. Tables 9 & 10 list them based on inputs from 
the recent edition of the WHO 2008 classification of hematopoietic 
neoplasms. 
Table 9: IHC markers used in subtyping AML [20] 
AML with minimal 
differentiation 
CD34, CD38, HLA – DR, CD33, TdT, 
CD7. 
AML without maturation MPO, CD13, CD33, CD117, CD34,HLA – DR, CD7. 
AML with maturation CD13, CD33, CD65, CD11b, CD15, HLA 
- DR, CD34  
Acute Myelomonocytic 
Leukemia  
CD13, CD33, CD65, CD15, CD14, CD4, 
CD11b, CD64, CD36, CD163, 
LYSOZYME 
Acute monoblastic and 
monocytic Leukemia 
CD14, CD4, CD11b, CD64, CD36, 
CD163, LYSOZYME, CD117, HLA – DR 
Acute erythroid Leukemia HEMOGLOBIN A, GLYCOPHORIN, CD71(low) 
Acute Megakaryoblastic 
Leukemia CD41, CD61, CD42 
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Table 10: IHC markers used in subtyping ALL [19] 
B lymphoblastic leukemia/ 
lymphoma 
CD19, CD79a, CD22, CD10, CD24, 
PAX5, TdT, CD20, CD34 
T lymphoblastic leukemia/ 
lymphoma 
CD1a, CD2, CD3, CD4, CD5, CD7, 
CD8,TdT, CD99, CD34 
 
OVERVIEW OF THERAPEUTIC STRATEGIES FOR AML: 
Over many decades, combination chemotherapy was the standard modality 
in the treatment of AML. This consisted of an early induction regimen 
which included cytarabine 100mg/m2 by continuous infusion for a period of 
7 days, followed by 3 days intravenous injections of Daunorubicin. The 
induction therapy was followed by a consolidation phase which was either 
chemotherapy with high dose cytarabine for 4 cycles or chemotherapy along 
with autologous hematopoietic stem cell transplantation or allogenic 
hematopoietic stem cell transplantation. [34] 
With advances in the fields of cytogenetics and molecular genetics, the 
European Leukemia Network (ELN) has come up with a classification in the 
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year 2010 which prognosticates leukemic patients into 4 categories as 
shown in table 11. 
The treatment of patients in “favorable” category is same as the standard 
regimen but the dose of Cytarabine and Daunorubicin could be increased. [35] 
Table 11: European Leukemia Network (ELN) prognostic system [36] 
Genetic group Subsets 
Favorable  
t(8;21)(q22;22), RUNX1 – RUNX1T1, inv(16)(p13.1q22) 
or t(16;16)(p13.1;q22),CBFB-MYH11 
Mutated NPM1 without FLT3 – ITD 
Mutated CEBPA 
Intermediate I 
Mutated NPM1 andFLT3 – ITD 
Wild - type NPM1 and FLT3 – ITD  
Wild - type NPM1 without FLT3 – ITD 
Intermediate II 
 t(9;11)(p22;q23), MLLT3 – MLL  
Cytogenetic abnormalities other than favorable or adverse 
Adverse  
inv(3)(q21;q26.2) or t(3;3)( q21;q26.2), RPN1 – EVI1, 
t(6;9)(p23;q34), DEK – NUP214, t(V;11)(V;q23), MLL 
rearranged, - 5 or del(5q), - 7, abnl(17p), complex 
karyotype. 
   
For treatment of patients in “intermediate” category, newer drugs like 
nucleoside analogs can be added to Cytarabine. Holowieki suggested the 
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addition of Cladarabine which resulted in higher cure rates. [37] Faderi et al 
published that addition of Clofarabine (a newer drug in the same category) 
in the treatment of elderly AML patients, resulted in higher survival and 
cure rates. [38] 
In patients with FLT3 mutations, drugs with FLT3 inhibition were 
introduced. Sorafenib is one such drug. [38] 
  Treatment protocols of AML in the “adverse group” are not clear. While 
some have advocated standard therapy at higher doses, many studies counter 
this argument. Many of the patients in this category are being treated with 
newer molecules as part of drug trials. These molecules include Azacitidine 
and Decitabine. Preliminary results are not encouraging and many of these 
patients have been finally treated with Hematopoietic Stem Cell 
Transplantation [36]. 
OVERVIEW OF THERAPEUTIC STRATEGIES FOR ALL: 
There has been a phenomenal improvement in 5 year survival for pediatric 
patients with ALL. For instance, it has risen from 3% in 1960 to 84% in the 
1996 – 2004 SEER data. The children’s oncology group developed a 
consensus classification to categorize childhood ALL into risk groups. 
Precursor T – ALL patients are at higher risk than precursor B – ALL. 
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Children with pre B – ALL were further classified into low and high risk 
within this subset based on cytogenetic studies. Thus, those children who 
tested positive for BCR/ ABL and or t (9; 22) were categorized as high risk. 
Further, children without this cytogenetic abnormality but did not respond to 
standard induction therapy are also classified as high risk. 
Currently  ALL in children is treated by a multipronged modality which 
includes remission induction by vincristine, predsinolone and intrathecal L – 
asparginase, CNS directed therapy by cranial irradiation, reinduction 
therapy using methotrexate in addition to the same drugs used for induction 
of remission and maintenance therapy using daily oral mercaptopurine and 
weekly oral methotrexate.[39] 
Treatment protocols for ALL in adults have been inspired by pediatric 
regimens. However, treatment outcomes have only improved from 3% in 
1960 to 30 – 40% in 1996 – 2004 SEER data. Allogenic stem cell 
transplantation and newer molecules such as Nelarabine and Clofarabine are 
being used with increasing success rates. [40] 
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Before initiating the study, we submitted a protocol of our proposed 
research work in the prescribed format to the Institute Human Ethics 
Committee. Our proposal was identified as exempt from review with a note 
that the researchers need to sign a declaration on confidentiality which we 
conformed to.  
1st January, 2008 to 30th June, 2012 was chosen as our study period. The 
peripheral smear registers of this period were accessed and cases diagnosed 
as acute leukemia were noted down. We noted the parameters such as OP / 
IP number, age, sex, referring unit, diagnosis offered and further tests 
recommended (if documented). We logged into the ‘Patient Result Detail’ 
page of our Hospital Information System using a secured login. Using the 
OP number as the unique identifier, we traced the case records of all the 
other investigations performed on each case. We noted the results of the 
bone marrow aspiration (BMA) and bone marrow trephine (BMT) biopsy 
studies wherever available. From these sheets we noted the unique numbers 
allotted to them by the divisions of Clinical Pathology & Histopathology of 
the Department of Pathology. These numbers are allotted for easy 
traceability of slides, blocks and reports. 
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The support staff retrieved all the slides (BMA & BMT) and duplicate 
copies of the reports. We also procured all the blocks of BMT tissues.  
We reviewed all the slides with the reports of results. We paid particular 
attention to the morphology of the blasts in the peripheral smear and bone 
marrow aspirate smears. The cytochemistry slides wherever available were 
also reviewed.  
Using a master chart, we made a note of cases where the diagnosis of the 
type of acute leukemia was made on morphology alone and those that were 
diagnosed after cytochemistry was performed.  We also noted those that 
bore, just a final diagnosis of acute leukemia with no mention of the type. 
Finally we shortlisted all those cases which had all the three diagnostic 
material needed to complete our study, viz., Peripheral smear, Bone marrow 
aspiration smear and Bone marrow trephine biopsy specimen and blocks. 
Procedure of staining peripheral smears: 
All the peripheral smears are stained in the clinical pathology laboratory 
using commercially prepared Leishman solution and in-house prepared 
buffer solution (pH 6.8). The staining procedure followed in the laboratory 
is an adoption of the technique described in the textbook ‘Medical 
Laboratory Science Theory & Practice’ by Ochei J & Kolhatkar A. [41]  
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Briefly, thin smears of peripheral blood were prepared by wedge method, air 
dried for 10 minutes, stained with Leishman’s stain for 2 minutes, diluted 
with buffered water, mixed well by gentle blowing, left undisturbed for 12 
minutes, washed in tap water and dried. 
Procedure of staining bone marrow aspirate smears: 
Bone marrow aspirations were performed by the treating physicians in the 
procedure room of the wards. The pediatricians performed it in the minor 
operation theatre. The material obtained was received by the technician of 
the clinical pathology lab posted to assist the team. The bone marrow 
particles were immediately placed on glass slides and, films (approximately 
3 – 5 cm in length) were made, as early as possible, with smooth edged 
spreader slides without delay. Whenever the procedure was followed by a 
trephine biopsy of the bone marrow, touch imprints were made after which 
the material was transferred to a pre labeled container, containing 10 ml of 
B5 fixative. 
The bone marrow slides were stained using Giemsa stain. The procedure 
followed in the lab is based on the Standard Operating Procedures for the 
Preparation and Staining of Blood Films published online by the Regional 
Office for South East Asia of the World Health Organization. [42] 
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The key reagents used were absolute methanol and Giemsa stain [diluted 
with buffered water- nine volumes and at pH 6.8]. The procedure followed 
in the CP lab to stain the bone marrow smears is detailed below. 
The smears were thoroughly air dried and quickly fixed by immersing in 
methanol jar for a period of 20 minutes after which they were placed in a jar 
containing Giemsa stain. The slides were then washed in four changes of 
water and kept in water subsequently, for 5minutes, for differentiation. The 
back of the slides were wiped with a clean piece of gauze. Slides were 
allowed to air dry in a tilted position and finally the slides were mounted. 
The stained smears were examined under scanner (40x), low power (100x), 
high power (400x) and oil immersion (1000x) objectives. The reporting 
format included information on cellularity, erythroid series (including 
maturation pattern), myeloid series (including an observation on sequential 
maturation) and megakaryocytes (including nuclear lobations). A 500 cell 
differential count was done on the cell trails and extrapolated to 100. A 
detailed description of the morphology and percentage of blasts was 
observed and documented.  
Cytochemistry was performed in many cases. The cytochemical stains used 
were myeloperoxidase stain and Periodic Acid – Schiff. Esterase stains were 
not done. The procedures followed in the laboratory are guided by those  
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described in the textbook authored by Barbara A Brown and titled 
‘Hematology: Principles & Procedures’. [43] 
Myeloperoxidase staining: 
Reagents required: 
1. Buffered formal acetone (fixative) 
2. 3,3’ – diaminobenzidine (substrate) 
3. Phosphate buffer at pH 7.3 (buffer) 
4. Hydrogen peroxide (30%) 
5. Aqueous haematoxylin (counterstain) 
6. Distrene dibutyl phthalate xylene (DPX) -  Mountant 
Staining Method: 
• Air dried smears were kept in cold buffered formal acetone for 30 
seconds. (for fixation) 
• The slides were rinsed thoroughly in running tap water and were air 
dried. 
• Slides were incubated for 10 minutes in the working solution. 
(Mixture of 30 mg of diaminobenzidine in 60 ml of phosphate buffer) 
• 120µl of hydrogenperoxide was added and mixed well. 
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• Slides were counterstained with haemotoxylin for 5 minutes. 
• Slides were washed in running tap water. 
• The back of the slides was wiped with a clean piece of gauze.  
• Slides were allowed to air dry in a tilted position. 
• Finally, the slides were mounted. 
 
Interpretation of myeloperoxidase stained smears: 
Peroxidase enzyme is present in the granules of myeloid series and to a 
lesser extent in those of the monocytes. By this technique the granules are 
stained reddish-brown. Blasts were examined for the presence or absence of 
these peroxidase staining granules. Other precursors of granulocytes and 
granulocytes per se served as internal quality controls. In positive cases, the 
pattern of staining - diffuse cytoplasmic or granular was also noted. 
Periodic Acid – Schiff (PAS) staining:  
Reagents required: 
1. Absolute Methanol (fixative) 
2. 1% periodic acid 
3. Schiff’s reagent 
4. Harris haematoxylin (counter stain) 
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5. Distrene dibutyl phthalate xylene (DPX) -  Mountant 
Staining method: 
• Slides were fixed in absolute methanol for 15 minutes. 
• Rinsed in tap water and air dried. 
• Slides were flooded with 1% periodic acid for 10 minutes. 
• Slides were rinsed in running tap water for 10 minutes and air dried 
• Slides were immersed in a coplin jar containing schiff’s reagent for 
30 minutes with the lid closed. 
• Slides were rinsed in running tap water for 10 minutes 
• Counterstained with harris haematoxylin for 5 minutes. 
• Differentiated in 1% acid alcohol for 10 seconds. 
• Washed well in running tap water for 10 minutes. 
• The back of the slides were wiped with a clean piece of gauze.  
• Slides were allowed to air dry in a tilted position. 
• Slides were mounted.  
Interpretation of PAS stained smears: 
In haemopoietic cells a positive reaction indicates the presence of glycogen 
in the cytoplasm. The reaction product stains bright magenta to red. 
Myeloblasts are either negative or show a weak diffuse positivity.  
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Lymphoblasts may show block positivity. Mature granulocytes whose 
cytoplasm stained diffusely positive were used as the internal control.   
Bone marrow trephine biopsy: 
The trephine biopsies were received in B5 solution. After two to four hours 
of fixation in this solution, the biopsy was fixed subsequently in 10% 
formalin for at least 12 hours, following which they were decalcified by 
immersing in a Coplin jar containing 10ml of nitric acid and 100ml of 
distilled water. The specimens were processed in an automatic tissue 
processor and embedded in paraffin wax. 3-4µm sections were cut and 
stained with hematoxylin and eosin. The staining procedure was suited to 
adjust to the preliminary fixation by B5 as the interfering mercury pigment 
needed to be removed. [32] 
Modified Hematoxylin and eosin (H&E) staining: - 
Reagents required: 
1. Harris hematoxylin 
2. Eosin y 1% 
3. Acid alcohol 1% (1% hydrochloric acid in 70% alcohol) 
4. Xylene 
5. Graded alcohols (70%, 95%, 100%) 
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6. 3% Lugol’s iodine (for removal of mercury pigment of B5 fixative) 
7. 2.5% sodium thiosulphate  
8. Distrene dibutyl phthalate xylene (DPX) -  Mountant 
Staining method: 
• Sections were deparaffinized by two changes in xylene. 
• Hydrated through descending grades of alcohols to water. 
• Treated with 3% Lugol’s iodine for 5 minutes 
• Washed thoroughly in running tap water  
• Cleared  in 2.5% sodium thio sulphate for 5 minutes 
• Washed thoroughly in running tap water  
• Stained with Harris haemotoxylin for 5 minutes 
• Washed in running tap water for 5 minutes (for blueing of sections) 
• Differentiated in 1% acid alcohol for 10 seconds 
• Washed in running tap water for 10 minutes, till the sections turned 
blue again. 
• Stained with 1% eosin Y for 2 minutes. 
• Washed in running tap water for 5 minutes. 
• Dehydrated through ascending grades of alcohols. 
• Cleared in xylene.  
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• Mounted with DPX. 
Evaluation of bone marrow trephine biopsy sections stained with H&E: 
Reports of the trephine biopsy slides contained information on adequacy ( as 
a general rule, biopsies with at least seven to ten partially preserved inter - 
trabecular areas were considered as adequate), cellularity for the 
corresponding age, location and the proportion of normal hematopoietic 
elements, blasts, stroma etc. 
Immunohistochemistry on bone marrow trephine sections:  
Immunohistochemistry was performed on the blocks of those cases which 
had slides and reports of peripheral smear and bone marrow studies, to 
detect the expression of Myeloperoxidase (MPO), Terminal 
deoxynucleotidyl transferase (TdT), Cluster of Differentiation 3 (CD3) and 
Cluster of Differentiation 20 (CD20) in tissue sections by means of the 
supersensitive polymer – Horse Raddish Peroxidase (HRP) detection 
system. The general procedure followed is that described in the 1st edition of 
Diagnostic Immunohistochemistry authored by David J Dabbs. [44] The 
incubation time was modified as recommended in the kit insert of the 
manufacturer of the primary antibody (Biogenex). 
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Reagents used: 
1. Primary antibodies available in liquid form (Biogenex, San Ramon, 
USA):  
* Anti – CD3 (T cell) mouse monoclonal [clone, PS1]. 
* Anti – CD20 (B cell) mouse monoclonal [clone, L-26]. 
* Anti – Myeloperoxidase (MPO) rabbit polyclonal. 
* Anti – Terminal deoxynucleotidyl transferase (TdT) mouse 
monoclonal [clone, TdT88]. 
2. Poly HRP reagent – anti rabbit and anti mouse Immunoglobulin G 
(IgG) complex linked to Horse Radish Peroxidase enzyme. 
3. 3, 3’ Diamino benzidine hydrochloride (DAB) – Chromogen. 
4. Citrate buffer at pH 6. (2.94 grams of Tri sodium citrate dissolved in 
1000ml of distilled water to which 5ml of 1N Hcl was added) 
5. Hydrogen peroxide (H2O2) 3% - To block the activity of endogenous 
peroxidase enzymes. 
6. Phosphate buffered saline (PBS), 0.01Molar and at a pH of 7.6. This 
was prepared in-house as follows: 
• Di basic sodium phosphate, anhydrate (Na2HPo4)    - 17.5 grams. 
• Monobasic potassium phosphate, anhydrous (KH2Po4)    - 2.5 grams. 
• Sodium chloride (NaCl)      - 17 grams. 
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• These three substances were dissolved in 1000ml of distilled water. 
7. Blocking agent (phosphate buffered saline containing casein and 15 
mM sodium azide) – used to block binding of nonspecific proteins. 
8. Harris hematoxylin – ( for counter staining) 
9. Xylene 
10. Graded alcohols (70%, 95% and 100%) 
11. 3% Lugols iodine (to remove the mercury pigment of B5 fixative) 
12. 2.5% Sodium thiosulfate solution 
13. Enhancer  
14. Distrene dibutyl phthalate xylene (DPX) – mountant. 
Principle of the detection system: 
Antigens present in blasts were detected by a two step process. In the first 
step, the unlabelled primary antibody (MPO, TdT, CD3 and CD20) against 
the antigen to be identified was applied. They would bind to the 
corresponding epitopes present on the blasts. 
Next step was the addition of a dextran polymer, containing many 
molecules of horse radish peroxidase enzyme to which was attached already 
a linker secondary antibody, directed against the primary antibody. 
 
  
 
When a chromogen 3, 3’ Diamino benzidine hydrochloride (DAB) 
applied, the signal was amplified as several
reacted with diverse antigenic sites present in the primary antibody. 
This principle is illustrated below in a schematic diagram.
Method: 
• Paraffin blocks of 
taken and fresh sections 4
onto a poly – L – 
• Paraffin blocks of the following normal tissues (spleen, thymus, 
tonsils) were chosen and fresh sections 4
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floated on to a poly – L – lysine coated slide to serve as controls for 
the antibodies (spleen for MPO, thymus for TdT and tonsils for both 
CD3 & CD20). 
• The same procedure was followed for both cases and control slides. 
• Slides were incubated overnight in an incubator at a temperature of 
370C. 
• Then slides were deparaffinized in two changes of xylene 10 minutes 
each. 
• Rehydrated through descending grades of alcohols for 5minutes in 
each. 
• Treated with 3% Lugol’s iodine for 5 minutes. 
• Washed in running tap water. 
• Cleared with 2.5% sodium thio sulphate solution for 5 minutes. 
• Rehydrated by washing well in running tap water for 5 minutes. 
• Heat mediated antigen retrieval was done using a pressure cooker at 
950C, for 10 minutes. 
• The cooker was kept inside sink with water for 20 minutes and 
brought to room temperature. 
• Slides were washed in PBS buffer at pH 7.6 twice, each wash for 5 
minutes. 
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• To block the endogenous peroxidase activity, the slides were 
immersed in 0.3% hydrogen peroxide for a period of 20 minutes. 
• Slides were washed in PBS buffer at pH 7.6 thrice, each wash for 5 
minutes.  
• To block nonspecific protein binding, the slides were incubated for 10 
minutes with 100µl of blocking solution (Power block, Biogenex). 
• Slides were washed in PBS buffer at pH 7.6 thrice, each wash for 5 
minutes. 
• Then slides were incubated with 100µl of primary antibodies (MPO, 
TdT, CD20 and CD3, Biogenex) on the respective sections. The 
incubation period was as follows; 
               MPO – 30 minutes at room temperature 
               CD20 – 30 minutes at room temperature 
               CD3 – 1 hour at room temperature  
               TdT – 2 hours at room temperature 
• To increase the signal intensity, the slides were incubated with 100µl 
of an enhancer (Super enhancer, Biogenex) for 20 minutes.        
• Slides were washed in PBS buffer at pH 7.6 thrice, each wash for 5 
minutes. 
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• Slides were incubated with 100µl of polymer HRP (Horse radish 
peroxidase reagent, Biogenex) for 30 minutes. 
• Slides were washed in PBS buffer at pH 7.6 thrice, each wash for 5 
minutes. 
• Diamino benzidine (DAB) was freshly prepared by adding 1 drop of 
liquid DAB chromogen to 1 ml of stable DAB buffer. 100µl of this 
was added to the slides and incubated at room temperature 5 minutes. 
• Slides were washed well in running tap water. 
• Counterstained with Harris haemotoxylin for 3 minutes. 
• Washed well in running tap water. 
• Dehydrated in ascending grades of alcohols for 5 minutes each. 
• Sections were cleared in two changes of xylene, 10 minutes each. 
•  Mounted with Distrene dibutyl phthalate xylene (DPX).  
Evaluation of IHC staining:  
The slides were examined systematically under scanner (4x), low power 
(100x) and high power (400x) objectives. A well stained area without any 
nonspecific background staining was chosen to assess the antigen 
expression of the blasts. The reaction was considered positive if the 
following pattern of staining was observed in more than 10% of the 
neoplastic cells. [45] 
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MPO – brown colored cytoplasmic staining. 
TdT – brown colored nuclear staining. 
CD20 – brown colored membranous accentuation and some cytoplasmic 
staining. 
CD3 – brown colored membranous accentuation. 
The observations of Immunohistochemistry studies were documented in the 
master chart and results analyzed.                                
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During the study period between 1st January, 2008 and 30th June, 2012, the 
Clinical Pathology Laboratory (C.P. Lab) of PSG hospitals performed about 
eleven lakh tests. 58% of these were hematology tests while the remainder 
was composed of tests performed on urine, body fluids, stool, semen etc. 
Table 12 shows the breakup of the total tests performed in the C.P. Lab 
during the study period. 
Table 12: Break up of tests performed by the CP Lab during the study 
period. 
Broad category No of tests performed % of total tests 
Hematology tests 6,41,803 58% 
Non – hematology tests 4,56,747 42% 
Total tests performed 10,98,550  
 
46,227 of the hematology tests were peripheral smears. During the same 
period, 1088 bone marrow aspiration tests were performed. The remainder 
of the tests was Complete Blood Counts, Prothrombin Time, Activated 
Partial Thromboplastin Time, Reticulocyte count, ESR and isolated blood 
count requests such as Total WBC count, Hemoglobin, Hematocrit, Platelet 
count etc.  
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Table 13 shows the breakup of the hematological tests performed during the 
study period. Peripheral smears accounted for 7% of the total tests while 
bone marrow aspirations accounted for less than 0.2% tests of the total 
hematological tests. 
Table 13: Breakup of types of hematological tests performed by the CP Lab 
during the study period 
Test item Number of tests % of total tests 
Peripheral smear study 46,227 7% 
BMA smear study 1,088 0.16% 
Other tests such as CBC, PT, 
APTT, ESR etc 5,94,488 92.84% 
Total hematology tests 6,41,803  
 
Of the 46,227 peripheral smears and 1088 bone marrow aspiration smears, 
344 cases were diagnosed as leukemia. Table 14 depicts the breakup of the 
types of leukemias reported during the study period. 
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Table 14: Types of leukemias reported during the study period 
S.No Diagnostic category No. of cases 
1.  Acute leukemia 99 
2.  Chronic myeloid leukemia 130 
3.  Chronic lymphocytic leukemia 114 
4.  Chronic myelomonocytic leukemia 1 
5.  Total 344 
 
Thus acute leukemias comprise 28.7% of the total leukemias reported 
during the study period.  
There was a bimodal peak age of occurrence i.e., 0-20 years and 41-60 
years. The mean age was 39 years. Figure 1 shows the age distribution of 
the reported cases of acute leukemia. 
 
 
 
 
 
  
 
Figure 1: Age distribution of acute leukemia
 
Figure 2 shows the sex distribution of acute leukemia reported 
study period. Males slightly outnumber females.
Figure 2: Sex distribution of acute leukemia
16
14
4
0
5
10
15
20
25
0 - 10 11- 20 21 -
RESULTS
 
 
 
10
22
16
10
5
30 31 - 40 41- 50 51 - 60 61 - 70 71 - 80
NUMBER OF CASES IN EACH DECADE
MALE
56%
FEMALE
44%
sex distribution
 
70 
 
during the 
 
2
> 80
RESULTS 
 
71 
 
 
Test records of the 99 cases of acute leukemia were accessed. Bone marrow 
aspiration (BMA) study was performed on 47 of these cases. Bone marrow 
trephine biopsies were also formed on 40 of these 47 BMA cases (85%). 
Of the 99 cases diagnosed as acute leukemia in the peripheral smear/ bone 
marrow aspirate/ both, a definitive diagnosis of the type of acute leukemia 
based purely on the morphology, was possible in only 9 cases (Figure 3). 
All of these were acute myeloid leukemia. 6 cases were suspected to be 
acute lymphoid leukemia requiring further studies for confirmation. 3 others 
were suspected to be acute myeloid leukemia – myelomonocytic/ 
monoblastic type (AML- M4/5). Thus only 9% of acute leukemias could be 
typed with certainty using morphology alone.  
 
 
 
 
 
 
 
 
 
 
  
Figure 3: Distribution of types of acute leukemia reported on PS/BMA/
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or bone marrow aspiration smears. Of these, a definitive diagnosis on the 
type of leukemia was made on 8 cases (25%). Of the
(myeloperoxidase positive) 
with periodic acid Schiff
declared as non – contributory with a request to perform ancillary tests. 
Figure 4 shows the results of cytochemistry performed on 32 of the cases of 
acute leukemia. 
Fig 4: Distribution of types of acute leukemia following cytochemical 
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Of the 9 cases of AML diagnosed by morphology on Romanosky stained 
PS/BMA smears, cytochemistry was done in 7 cases. Of these, results of 
cytochemistry in 6 cases were corroborative with the morphological 
diagnosis i.e the blasts were positive for myeloperoxidase. On 1 case (AML 
– M2), cytochemistry was not contributory. 
6 cases were suspected to be ALL (L1 orL2) on morphological grounds. 
Cytochemistry was done in all of them. In 3 cases, the lymphoblasts showed 
classical cytoplasmic block positivity for PAS confirming the diagnosis. 
PAS was negative in the other 3. 
In 3 cases where a presumptive diagnosis of AML M4/M5 was offered, 
cytochemistry was done on all 3 cases. The blasts were negative for both 
MPO and PAS. Thus cytochemistry was not contributory in any of these 
cases. Table 15 is a summary of the results of cytochemistry. While only 9 
cases could be diagnosed by morphology, an additional 11 cases could be 
typed using cytochemical studies with Myeloperoxidase and Periodic Acid 
Schiff stains. 
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Table 15: Summary of results of cytochemistry 
Morphologic diagnosis 
on PS/BMA smears Cytochemistry 
Utility of results of 
cytochemistry (MPO & 
PAS) 
 
Done Not done  
Acute leukemia 32 49 
7 – diagnosed as AML 
1 – diagnosed as ALL 
24 – not contributory 
AML 7 2 6 – corroborative 1 – not contributory 
?ALL 6 0 3 – diagnosed as ALL 3 – not contributory 
? AML M4/M5 3 0 Not contributory in all 3 
Total 48 51 
11 cases typed as AML or 
ALL 
6 – corroborative with 
morphological diagnosis 
31 – not contributory 
Grand total 99  
 
Bone marrow trephine biopsy was performed in 40 of the total 99 cases of 
acute leukemia. Review of slides and blocks showed that 4 were inadequate 
for IHC studies. Hence immunohistochemistry was performed in 36 of the 
bone marrow trephine biopsies. Fresh sections from the blocks of all these 
cases were cut and immunohistochemistry was performed using four 
primary antibodies – Myeloperoxidase (MPO), CD20, CD3 and terminal 
deoxynucleotidase (TdT).  Table 16 shows a breakup of the diagnostic  
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status of the study population prior to the application of IHC markers. We 
have considered all those cases speculated to be ALL or AML on 
morphology (with cytochemistry also being not contributory), into the broad 
category of acute leukemia.  
Table 16: Diagnosis prior to the application of IHC studies 
Diagnosis No of cases 
Acute Leukemia       20 
AML 
Diagnosis by morphology 6 
11 
Diagnosis only after cytochemistry  5 
ALL 
Diagnosis by morphology 0 
5 
Diagnosis only after cytochemistry  5 
Total cases (study population for IHC studies) 36 
 
Of the 20 cases of acute leukemias, the IHC panel could type 18 of them as 
either myeloid or lymphoid (Table 17). Thus IHC has helped in subtyping 
90% of the cases of acute leukemia. 1 case did not express any of the 
phenotypes studied. Another case showed positivity for both lineages. 
 
 
  
 
Table 17: Subtypes of Acute Leukemia after IHC studies
Subtype of Acute Leukemia after IHC 
study
AML 
ALL 
Acute Leukemia of Ambiguous 
Not contributory 
Total 
 
Figure 5 illustrates the number of acute leukemias that could be typed using 
morphology or cytochemistry or IHC
Diagnosed 
only by IHC
51%
Figure 5: Subtyping of acute leukemia
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Table 18 shows that IHC had a 100% correlation with the subtype of acute 
leukemia that was diagnosed prior to IHC studies, either by morphology or 
cytochemistry. All the AML cases were positive for MPO and they were 
uniformly negative for CD20, CD3 and TdT. 4 of the ALL cases were 
positive for CD20, 1 was positive for CD3 and 3 were positive for TdT. 
 
Table 18: Results of IHC on acute leukemia already typed by morphology or 
cytochemistry 
Diagnosis No of cases MPO CD20 CD3 TdT 
AML 11 11/11 0/11 0/11 0/11 
ALL 5 0/5 4/5 1/5 3/5 
 
Table 19 shows the overall summary of the phenotypes of the immature 
cells after the performance of IHC studies. Of the ALL cases, 83% were of 
B cell lineage (ie CD20 positive) and TdT was positive in 90% of them. 
17% of ALL were of T cell lineage and 1 of them was positive for TdT. 
None of the AML blasts were positive for TdT. Overall 31% of the acute 
leukemia was positive for TdT.  
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Table 19: Summary of the Phenotypes of Acute Leukemia. 
Diagnosis No of cases MPO CD20 CD3 TdT 
AML 22 22/22 0/22 0/22 0/22 
ALL 12 0/12 10/12 2/12 10/12 
Acute leukemia of 
ambiguous lineage 1 1/1 0/1 1/1 1/1 
Not contributory 1 0/1 0/1 0/1 0/1 
All leukemias 36 23/36 10/36 3/36 11/36 
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PSG Hospitals, a tertiary care hospital, is a teaching affiliate of PSG 
Institute of Medical Sciences & Research, Coimbatore. The hospital caters 
to an average outpatient strength of 1060/day and an inpatient strength of 
900/day.  
The clinical pathology laboratory (CP Lab) receives samples from these 
patients and also from those attending the peripheral outreach clinics 
affiliated to the PSG Hospitals. 
The hospital, as a policy, performs a few definitive screening investigations 
on all its new patients, which include Complete Blood Counts and Urine 
analysis. Hence they are the most common tests performed in the CP Lab. 
Peripheral smears are generally requested as a follow up after CBC tests. 
Hence they account only for 7% of the hematology tests. Bone marrow 
studies are performed most often, only upon the advice of the pathologist, 
except under certain situations (e.g. work up of lymphoma, myeloma, 
metastatic disease, pyrexia of unknown origin etc). 
The CP lab maintains a register of all the peripheral smears reported by the 
pathologists. This register has the information on patient name, age, sex, IP/ 
OP number, referring unit/consultant, diagnosis and comments. This register 
was therefore useful in identifying all those peripheral smears which bore a  
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diagnosis of leukemia or were suspected to be leukemia with 
recommendations to perform ancillary tests such as bone marrow aspiration 
(BMA) and bone marrow trephine (BMT) biopsy. 
PSG Hospitals has one of the advanced electronic data processing centers 
with well trained staff and facilities. The Hospital Information System 
(HIS), designed in – house, helped us to jot down results of all the 
information on the tests relevant to our study i.e. cytochemistry, BMA and 
BMT (hematoxylin & eosin stained section studies). 
We observed that during the study period, the CP lab had reported 344 cases 
of leukemia, all types inclusive. Thus on an average, 76 new cases of 
leukemia were reported each year. This is significantly higher than the 
observation made by D’ Costa GG et al, where they found an annual 
occurrence of about 24 cases over a 10 year period.[46]  
Non – Hodgkin lymphoma and leukemia are listed in the top 10 leading 
sites of cancer in many centers that have contributed to the development of 
an Atlas of Cancer in India. [47] Xie Y, et al published their observations on 
the trends in leukemia in USA, over a period of 25 years (1973 - 1998). 
They noted that there was an overall increase in occurrence of leukemia in 
people lesser than 20 years old, most of which was due to an increase in the  
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incidence of ALL. However, the number of cases of leukemia in people 
older than 20 years decreased, chiefly due to a decline in the incidence of 
CML and CLL. There was no change in the incidence of AML. [48] 
Acute leukemias comprised 28.7% of all leukemias in our study. This is 
much lesser compared to D’Costa et al’s observations, where they 
comprised 58% of all leukemias. Thus there appears to be an obvious 
geographical variation in the pattern of leukemias within India. 
The peak age of occurrence of acute leukemia which showed a bimodal 
pattern compared well with D’ Costa et al’s study and Anuradha Kusum et 
al’s study. [49] 
While our study showed only a slight male preponderance (M:F = 1.3:1) in 
the  sex incidence of acute leukemias, a higher occurrence in men was noted 
in D’ Costa et al and Anuradha Kusum et al studies i.e. 2.7:1 and 2.3:1, 
respectively.[46],[49] 
All acute leukemias are required to be classified either as AML or ALL. 
This is crucial for 2 interdependent reasons – one, to choose the most 
appropriate ancillary investigation for exact sub typing and second to offer 
the most appropriate therapy. Ancillary tests are either cytogenetic studies 
or flow cytometry or a combination of both. The advent of targeted gene  
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therapy has made it imperative for this sub typing to be done. 
Parenthetically, as ancillary tests are very expensive, unless one is sure 
about the blast lineage, specific ancillary tests cannot be asked for. 
Our study showed that a definitive sub typing of acute leukemia as AML or 
ALL, purely by morphology, could be made in only 9 of the cases. The CP 
lab used only two cytochemical markers (viz myeloperoxidase and periodic 
acid Schiff), in the cases wherever cytochemistry was performed. Sudan 
black B was used infrequently. Hence it was not used in our data collection 
tool. Usage of these two cytochemical markers had helped in the typing of 8 
more cases of acute leukemia. Thus, of the 99 cases of acute leukemia, only 
17 cases could be sub typed as AML or ALL on morphology and 
cytochemistry. 14 of these 17 cases of acute leukemia were diagnosed as 
acute myeloid leukemia because, in all of these cases, the myeloblasts 
showed diagnostic Auer rods which are crystalline structures seen only in 
AML or in high grade myelodysplastic syndrome. They are never seen in 
lymphoblasts. [50] All the three cases of ALL could only be diagnosed after 
cytochemistry where the PAS reaction showed block positivity. Loffler H et 
al opine that ALL diagnosed by cytochemistry must be confirmed by 
immunophenotyping in all the cases. [51] 
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The FAB system which relied solely on morphology and cytochemistry 
continues to be used for the preliminary morphological assessment, but 
clearly, this is not enough. The recent WHO classification of hematopoietic 
neoplasms therefore relies extensively on immunophenotyping and of 
cytogenetic and molecular genetic analysis. [20] 
3 cases during the study period were diagnosed empirically as AML 
M4/M5. Review of the slides of these cases showed a preponderance of 
monoblasts and its derivatives with scarce myeloblasts. The monoblasts 
were large with abundant cytoplasm and an almost round nucleus. Faint 
granules and vacuolations were seen in some of them. All the 3 cases were 
negative for cytochemistry with myeloperoxidase and PAS. It would have 
been prudent if the cytochemistry panel included non specific esterases such 
as alpha napthyl butyrate (ANB) and alpha napthyl acetate (ANA) as they 
would have helped in the confirmation of monoblasts, promonocytes and 
monocytes. The WHO recommends a combination of 2 esterases in such 
cases, such as any one of the 2 non – specific esterases and 1 specific 
esterase such as naphthol – ASD – chloracetate esterase, so that the former 
would identify monocytic lineage cells and the latter, neutrophil lineage 
cells. 
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Using the HIS software, we had observed that in only 40 of the 99 cases of 
acute leukemia, was a bone marrow trephine biopsy done. On reviewing the 
slides 4 were excluded. 2 of them showed cartilage, cortical bone and sub 
cortical space only. Trabecular bone and marrow spaces were not seen. The 
other 2 cases had blood clots and cutaneous tissue only. Hence the final 
study population i.e. cases diagnosed as acute leukemia and had trephine 
biopsy blocks available for IHC studies, was 36. 
Immunophenotyping of the leukemic blasts is essential for the diagnosis and 
confirmation of acute leukemia into 1 of the 2 types (AML or ALL). 
Immunophenotyping refers to the identification of specific characteristic 
nuclear, cytoplasmic or cell surface antigens expressed by the leukemic 
cells. This is achieved by the recognition of these specific antigens by 
labeled antibodies. 
The detection system can either be flow cytometry or 
immunohistochemistry. Till recently, flow cytochemistry was preferred over 
immunohistochemistry, because it could be performed quickly and allows a 
more precise quantification of the percentage of positive cells. The same 
cell could express many types of antigens and these when bound by 
appropriate labeled antibodies, could be identified by forward and sideward  
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light scatter. [52] However, flow cytometry is very expensive, out of reach for 
the common man and technically non-feasible to be performed on archived 
tissues. IHC on the other hand, is a two dimensional system and generally 
involves application of 1 specific antibody per section. However, current 
IHC systems use multicolor combinations and 3 to 5 different antigens can 
be identified on the same section. 
Paraffin section IHC is a simple tool requiring skilled personnel and very 
little of equipment. Immunophenotyping of leukemic cells on tissue sections 
used to be infamous because of lack of consistent results. However, in the 
late 1990s there had been major advancements in the techniques of IHC, 
especially on the unmasking of antigenic epitopes on the paraffin tissue 
sections. This, coupled with the increased availability of commercial 
antibodies for lineage determination, has resulted in the resurgence of the 
use of IHC on bone marrow trephine tissues. [30] The WHO in its most 
recent issue on classification system, acknowledges that IHC can be used as 
a diagnostic tool for immunophenotypic analysis. [20] 
Literature is chocked with information on various IHC panels that can be 
used in the sub typing of acute leukemia. Tables 8 to 10 summarize the 
various markers that can be used to diagnose AML and ALL, including their  
DISCUSSION 
 
87 
 
 
subtypes. However, it is prudent that every laboratory develops its own 
inventory of IHC panel markers keeping in mind the commonality of types 
and finances involved. 
Anti MPO, CD13 and CD33 are the 3 IHC markers used consistently to 
detect blasts of myeloid lineage, by the 3 major conglomerates in 
hematology namely, European Group for the Immunological 
characterization of Leukemias (EGIL), US – Canadian Consensus Group 
(USCC) and British Committee for Standards in hematology (BCSH).[52] Of 
these CD13 and CD33 are best detected by flow cytometry. Anti MPO, 
however is best detected by IHC and has a very high specificity for myeloid 
lineage. [53] Hence anti MPO was the first to be included in our panel. We 
were aware that AML-M5 may not be picked up. However AML-M5 is 
rarely reported in our centre and monoblasts have a morphology distinct 
from myeloblasts. 
CD19, CD20, CD10 are the 3 markers common to all the 3 panels (EGIS, 
USCC & BCSH) for the detection of lymphoblasts of B cell type. CD19 is 
commonly used in Flow Cytometry and is not preferred for IHC studies as 
reliability tests are incomplete.[28] CD10 can be detected both by flow 
cytometry and immunohistochemistry. However a proportion of normal  
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hematogones also express CD10. [52] Hence CD20 was the 2nd marker to be 
included into our panel. 
CD 2 is the only IHC marker that is found in all the 3 panels of the expert 
groups, to detect lymphoblasts of T cell lineage. CD3 and CD7 are common 
to 2 systems. Hence we had to choose between CD2, CD3 and CD7. 
Chaung SS et al observed that anti CD3 specifically stained T lymphocytes 
on paraffin sections. [53] They also noted that it was non-reactive with B 
lymphocytes, granulocytes and non hematopoietic tissues. Hence CD3 was 
the 3rd marker to be included in our panel. 
The last to be included in our panel was TdT. This is a marker of immature 
hematopoietic and lymphoid cells. It is not lineage specific. It is positive in 
many of the ALL (B subtype in particular) and a few cases of AML (AML 
M0, M1). [52] 
Prior to the application of IHC on tissue sections, 20 of the 36 cases of the 
study population were acute leukemia i.e., they could not be typed as 
myeloid or lymphoid.  However, 18 of them could be clearly categorized as 
either AML or ALL after the application of our IHC panel (Colour plates 1 
& 2). Thus the lineage of 90% of acute leukemia could be identified. This 
compares well with the observations made by Arber DA et al who noted that  
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96% of acute leukemias could be sub typed effectively. However, their IHC 
panel included CD34, CD43, CD68, CD79a and HLA – DR in addition to 
the four used by us. The authors also observed that the lineage of the blasts 
could still be determined accurately even when the results are extrapolated 
to 4 specific IHC markers viz., CD3, CD79a, MPO and TdT. The authors 
conclude their paper noting that, if CD20 replaced CD79a, it could pick up 
rarer cases of ALL which are negative for CD79a and are positive for 
CD20. [30] 
A similar study was performed at the Kidwai Memorial institute of 
Oncology located at Bangalore. In addition to the 4 markers used in our 
study, they had also used CD68 and F8RA. Even in this study, the authors 
have observed that a limited panel of the 4 markers (as was used in our 
study) was effective enough to type acute leukemia as AML or ALL. They 
also noted that this panel has a distinct cost advantage compared to flow 
cytometry. 
1 case of acute leukemia expressed both myeloid and lymphoid phenotypes 
i.e. MPO, CD3 and TdT. The recent WHO classification of hematopoietic 
tumors acknowledges a broad entity called acute leukemias of ambiguous 
lineage which include all those acute leukemias that do not express any  
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phenotype of differentiation and those that express antigens of more than 1 
lineage to such an extent that it may not be possible to assign any 1 lineage 
with certainty. Acute leukemias which express antigens of more than 1 
lineage are also termed as mixed phenotype acute leukemias (MPAL). 
These are rare and account for 4% of all cases of acute leukemia. [54] The 
occurrence of MPAL in our study population was 3% which is similar to 
that reported in literature. 
Results of all the 11 cases of AML and 5 of ALL that were diagnosed by 
morphology and cytochemistry corroborated well with IHC studies (Colour 
plates 3, 4 & 6). A much larger correlative study done by Browman GP et al 
showed a concordance of 99%. The authors opine that even though a 
morphological diagnosis of the type of acute leukemia is made, IHC has to 
be done for confirmation, as morphological assessment has a high inter-
observer discordance. [55] 
All the 3 cases which were suspected to be AML – M4/M5 and were found 
to be negative for cytochemistry, turned out to be AML on IHC (Colour 
plate 5 ). MPO was expressed randomly in about 20 – 40% of the immature 
cells. The remainder was negative for MPO and to the other 3 IHC markers 
of our study. These could be monoblasts and their derivatives. CD68 detects  
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them by flow cytometry. However it is not effective in IHC as all FAB types 
of AML are reported to express this antigen. Antibody against lysozyme 
may be useful in such cases. [30] 
1 case of acute leukemia was negative for all the 4 IHC markers used in our 
study. 4 types of acute leukemia can classify for this presentation. They are 
AML with minimal differentiation, acute monoblastic leukemia, acute 
erythroid leukemia and acute megakaryoblastic leukemia. Of these, TdT 
may occasionally be positive in AML with minimal differentiation and 
Acute megakaryoblastic leukemia. We reviewed the morphology and results 
of cytochemistry of this case. The blasts showed no evidence of 
differentiation and had very scanty, agranular deeply basophilic cytoplasm. 
Prominent nucleoli, numbering 1 to 4 were also seen. This morphology 
clearly ruled out the possibility of AML – M5 as monoblasts have a distinct 
morphology. The absence of irregular or indented nuclear contours and 
cytoplasmic blebs and pseudopods were against the typical morphological 
appearance of a megakaryoblast. Results of cytochemistry showed that the 
cytoplasm was negative for a PAS reaction. Hence pure erythroid leukemia 
is also unlikely. Therefore it is possible that, this is a case of AML with 
minimal differentiation. Upto 50% of cases of AML with minimal 
differentiation are negative for TdT. Hence the only way to confirm that this  
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is a case of AML with minimal differentiation is to test for CD34, CD38 and 
HLA – DR.  
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1. On an average, 76 new cases of leukemia are diagnosed each year in 
the clinical pathology laboratory of PSG Hospitals. Of these 28.7%, 
are acute leukemias. 
 
2. Acute leukemias had a bimodal peak age of occurrence i.e. 0 – 20 
years and 41 – 60 years. 
 
 
3. Acute leukemias had a mild male preponderance (M: F=1.3:1). This 
contrasts from other published data from Bombay and North India 
which showed a much higher male predominance (M: F=2.3 to 2.7:1). 
 
4. Only 9 cases of acute leukemia could be typed as AML or ALL 
purely by morphology. Another 10 cases could be typed using 
cytochemistry. 
 
 
5. A limited immunohistochemical panel of MPO, CD20, CD3 and TdT 
used in our study helped to type 90% of cases of acute leukemia  
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(where bone marrow trephine biopsy was performed) into AML or 
ALL. 
 
6. Results of all the acute leukemias that were diagnosed by morphology 
or cytochemistry had a 100% correlation with the results of 
immunohistochemistry. 
 
7. The IHC panel used also identified 1 case of AML of ambiguous 
lineage while another was negative for all the markers. 
 
8. Based on our results, we suggest the use of this limited panel of 
immunohistochemical markers that includes MPO, CD20, CD3 and 
TdT, for the routine evaluation of all acute leukemias in paraffin 
embedded tissues. For a resource poor country such as ours, it is 
easier to type acute leukemia using immunohistochemistry than by 
flow cytometry given the disadvantage of the costs involved with the 
latter. 
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Master Chart of cases where Immunochemistry study was performed. 
 
S. 
NO 
AGE/
SEX 
IP/OP 
NUMBER PS & BMA MORPHOLOGY REPORT 
CYTOCHEMISTRY IMMUNOHISTOCHEMISTRY 
MPO PAS MPO CD20 CD3 TdT 
1 48/F I08003476 Acute leukemia + - + - - - 
2 51/M I08014000 Acute leukemia + - + - - - 
3 5/M I08015070 ? ALL/ L1 - + - + - + 
4 51/F I08017278 AML M3 - + + - - - 
5 45/M I08019864 ? ALL / L2 - + - + - - 
6 52/F I08041085 Acute leukemia Not contributory - - + - 
7 81/M I08019401 ? ALL - + - - + + 
8 31/M I08038009 Acute leukemia Not contributory + - - - 
9 75/F I09035118 AML M2 + - + - - - 
10 18/M I09040507 ? ALL / L2 Not contributory - + - + 
11 45/M I09000925 ? ALL/ L2 - + - + - + 
12 51/M I09015241 Acute leukemia Not done + - - - 
13 57/F I09002317 ? AML M4/M5 + - + - - - 
14 14/M I09032945 Acute leukemia Not contributory - + - - 
15 1/M I09041399 Acute leukemia Not contributory - + - + 
16 19/M I09000046 Acute leukemia Not done + - - - 
17 3/F I09022081 Acute leukemia Not contributory - + - + 
18 45/F I10000926 Acute leukemia Not done + - - - 
19 24/F I10003606 Acute leukemia + - + - - - 
20 41/M I10005666 Acute leukemia + - + - - - 
21 39/M I10006895 AML M3 + - + - - - 
22 45/M I10032796 AML M2 Not contributory + - - - 
23 14/M I10001284 Acute leukemia Not contributory - - - - 
24 32/F I10017006 Acute leukemia Not contributory + - - - 
25 45/F I10035882 ? ALL / L2 - + - + - - 
26 65/M I10036764 Acute leukemia Not contributory + - - - 
27 65/M I11003513 Acute leukemia + - + - - - 
Master Chart of cases where Immunochemistry study was performed. 
 
S. 
NO 
AGE/
SEX 
IP/OP 
NUMBER PS & BMA MORPHOLOGY REPORT 
CYTOCHEMISTRY IMMUNOHISTOCHEMISTRY 
MPO PAS MPO CD20 CD3 TdT 
28 15/M I11006102 Acute leukemia - + - + - + 
29 74/M I11001123 ? AML M4/M5 Not contributory + - - - 
30 15/M I11018027 Acute leukemia Not contributory - + - + 
31 58/F I11027567 Acute leukemia Not contributory + - - - 
32 54/M I11030526 ? AML M4/M5 Not contributory + - - - 
33 22/F I11029963 Acute leukemia Not done + - - - 
34 47/F I12004086 Acute leukemia Not contributory + - - - 
35 44/M I12011269 Acute leukemia Not contributory + - + + 
36 21/F I12015708 Acute leukemia + - + - - - 
 
 A case of acute leukemia subtyped as acute myeloid 
leukemia by immunohistochemistry Color plate 1 
 
 
 
 
Peripheral smear reported as acute 
leukemia as there were no 
differentiating features; Leishman; 
x1000 
 
 
Hypercellular bone marrow aspirate 
smear composed of a monotonous 
population of undifferentiated blasts; 
Giemsa; x100 
 
 
 
 
 
Bone marrow trephine biopsy showing 
hypercellular marrow spaces replaced 
by undifferentiated blasts; H&E; x400 
 
 
 Blasts are diffusely positive for  
myeloperoxidase on IHC; x400 
 
 
 A case of acute leukemia subtyped as Acute Lymphoblastic 
Leukemia by immunohistochemistry Color plate 2 
 
 
 
 
Bone marrow smear reported as 
acute leukemia; Giemsa; x400 
 
 
Bone marrow section showing 
extensive replacement of marrow 
spaces by blasts; H&E; x40 
 
 
 
 
 
Blasts showing positivity for CD 
20 by IHC; x400 
 
 
 Blasts are also positive for TdT by 
IHC; x100 
 
 
 A case of acute myeloid leukemia diagnosed by 
morphology & confirmed by immunohistochemistry Color plate 3 
 
 
 
 
 
 
Peripheral smear reported as 
AML-M2 with an Auer rod in a 
myeloblast (arrow); Leishman; 
x1000 
 
 
Myeloblasts showing cytoplasmic 
granular positivity for 
myeloperoxidase; x400 
 
 
 
 Myeloblasts staining intensely positive for                                  
myeloperoxidase on IHC study; x1000 
 
 
 
 A case of acute promyelocytic leukemia diagnosed by 
morphology & confirmed by immunohistochemistry Color plate 4 
 
 
 Bone marrow smear reported as AML-M3 showing 
many promyelocytes and a myeloblast with an Auer rod 
(arrow); Giemsa; x1000. 
 
 
 
 
 
 Myeloblasts staining intensely positive for myeloperoxidase 
on IHC study; x1000 
                                 
 
 A case of acute leukemia suspected to be AML-M4/M5, 
diagnosed as AML by immunohistochemistry Color plate 5 
 
 Bone marrow smear reported as ?AML-M4/M5 showing 
many monoblasts with abundant cytoplasm and an 
occasional promonocyte; Giemsa; x1000. Myeloblasts 
were also seen elsewhere. 
 
 
 
 
 
 
 
 
Bone marrow trephine biopsy 
showing numerous blasts with 
abundant cytoplasm and occasional 
promonocytes with prominent 
nuclear folds; H&E; x1000 
 
 
 Some of the blasts are positive for 
myeloperoxidase on IHC, 
indicating that they are 
myeloblasts. Others are negative. 
These could be monoblasts and 
promonocytyes; x400 
 
 A case of acute leukemia suspected to be AML-M4/M5, 
diagnosed as AML by immunohistochemistry Color plate 5 
 
 A case of acute leukemia 
diagnosed with cytochemistry and confirmed by IHC
 
 
 
Peripheral smear reported as 
?ALL-L2. Blasts showing 
variation in size, occasional 
nucleoli and variable amounts of 
cytoplasm; Leishman; x4
 
 
 
 
 
Lymphoblasts showing positivity for CD20
study ; X 400
 
suspected to be ALL-L2
 
 
 
00 
 
 
Blasts showing typical block 
with PAS stain. The cytoplasm of the 
neutrophil which stains diffusely 
positive, serves as an internal control
x400. Inset shows lymphoblast with 
large magenta colored blocks; PAS;   
x 1000.  
 on IHC 
 
, Color plate 6 
 
positivity 
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